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Alzheimer’s disease (AD) is the most common cause of dementia worldwide, 
and is now the 5th leading cause of death in the United States. The pathologic 
hallmarks of AD include the deposition of extracellular plaques of aggregated 
amyloid-b (Ab) and intracellular neurofibrillary tangles of tau aggregates (NFTs). 
Autosomal dominant inheritance of AD has been attributed to genetic mutations in 
three key genes: amyloid precursor protein (APP), presenilin-1 (PSEN1), and 
presenilin-2 (PSEN-2). Together, these pathologic findings and genetics provided 
the framework for the amyloid cascade hypothesis, which states that Ab deposition 
is a necessary, early event that is upstream of the formation of NFTs, and is 
causative of AD. 
Despite this seminal work, the mechanisms underlying the clinical 
progression of AD is still poorly understood. This gap in our knowledge is due, in 
large part, to the lack of appropriate AD disease models. Specifically, rodent models 
of human neurodegenerative disease fail to completely recapitulate disease 
phenotypes. In the body of work that follows, we utilized recent advances in induced 
pluripotent stem cell (iPSC) and genome editing technologies to investigate two 
separate AD disease mechanisms: tau spreading and Ab production in familial AD 
(FAD) PSEN1 mutants. 
Using TALENs, we generated a transgenic donor iPSC line that harbors a 
transgene for inducing the expression of fluorescently tagged tau protein and a 
recipient iPSC line that expresses membrane anchored YFP. These cell lines, when 
differentiated into human cortical neurons and cultured together, demonstrated that 
tau is transferred between neurons. However, similar protein spreading was 
observed for the control cell line expressing only mCherry, suggesting that tau did 
not transfer by a unique mechanism in this culture system. 
With the hope of revealing new insights into AD mechanisms, we next used 
CRISPR/Cas9 to produce a series of isogenic iPSC lines that harbor discrete FAD 
PSEN1 mutations. These mutations in PSEN1 alter the relative amount of Ab 
peptides, specifically increasing the ratio of Ab 42:40 and Ab 42:38. Our results 
demonstrate that each mutation causes a reduction in the levels of both Ab40 and 
Ab38, as well as an increase in Ab42. These results support the model that FAD 
PSEN1 mutations cause a loss of protein function, in that PSEN1 cannot properly 
process Ab42 into smaller, less aggregation prone peptides. Consistent with this, we 
found that C-terminal fragments of APP (b-CTF) accumulate in neurons with 
homozygous FAD mutations in PSEN1. Additionally, we also observed defects in the 
processing of other g-secretase substrates such as N-Cadherin. Intriguingly, the Ab 
42:40 ratio and Ab40 levels correlated with disease onset in heterozygous mutants, 
while Ab42 levels correlated with disease onset in homozygous mutants, suggesting 
that these values could be predictive of disease progression in culture. 
These results are all consistent with a partial loss in PSEN1 function, 
extending our current understanding of how FAD PSEN1 mutations affect PSEN1 
function, and, perhaps more importantly, identifying a mechanistic perturbation that 
is common to the tested FAD mutations. Taken together, PSEN1 dysfunction results 
in production of larger, aggregation prone Ab peptides, as well as CTFs.  These 
insights may be important for ultimately understanding how these mutations cause 
FAD, which will be critical for developing effective therapeutics that slow or prevent 
progression of this devastating disease
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CHAPTER 1: INTRODUCTION 
Rationale for the following studies 
In 1907, German psychiatrist and neuropathologist, Alois Alzheimer, detailed 
the case of a 51 year-old woman in a Frankfurt mental health institution experiencing 
rapid memory loss and behavioral disturbances (Alzheimer, 1907; Stelzmann et al., 
1995). Upon autopsy, he noted that there were numerous “minute miliary foci” 
throughout the cortex caused by the “deposition of a special substance” (Alzheimer, 
1907). More than a century later, our understanding of Alzheimer’s disease (AD) has 
seen immense progress. However, AD remains puzzling, as its etiology, 
pathogenesis, and cure are still avidly pursued. 
AD is the most common form of neurodegenerative dementia worldwide. For 
several decades we have understood that AD is defined by the presence of 
extracellular plaques consisting primarily of amyloid-beta (Ab) (Tanzi et al., 1987), 
and intracellular neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau 
protein (Grundke-Iqbal et al., 1986; Wischik et al., 1988). While the vast majority of 
AD is sporadic, with no underlying genetic cause, families have been identified that 
carry autosomal dominant mutations in one of three genes, amyloid precursor 
protein (APP) (Goate et al., 1991; Hendriks et al., 1992; Janssen et al., 2003; Mullan 
et al., 1992; Peacock et al., 1993), Presenilin-1 (PSEN1) (George-Hyslop et al., 
1992; Schellenberg et al., 1992; Van Broeckhoven et al., 1992), and Presenilin-2 
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(PSEN2) (Rogaev et al., 1995), that cause FAD. These mutations are all involved in 
the accumulation of Ab, highlighting the central role of APP processing in the 
pathogenesis of AD. 
There are many models of AD, including rodents, invertebrates, and in vitro 
cell culture (Götz and Ittner, 2008; Weggen and Beher, 2012). However, all of these 
models fail to completely recapitulate disease phenotypes. Even the best in vivo 
models that come close to mimicking the disease still require massive 
overexpression of transgenes, and expression of multiple transgenes, in order to 
obtain measurable results. The failures of these models are likely attributed to the 
fact that AD is a disease of aging, and restricted to humans, making it difficult to 
model in other species that don’t develop the disease de novo or live long enough 
for the disease to develop (age of onset is over 20 years for even the most 
aggressive FAD mutations). Unfortunately, cell lines of human cortical neurons, the 
cells primarily affected by AD, simply do not exist as they are post-mitotic, making 
the disease difficult to replicate in vitro. 
Fortunately, the advent of the induced pluripotent stem cell (iPSC) system 
brought with it the possibility to generate better models of AD (Takahashi and 
Yamanaka, 2006). iPSCs are self-renewing stem cells derived from somatic cells, 
such as human fibroblasts, that can differentiate into any type of cell or tissue. Thus, 
iPSCs hold the potential of providing an inexhaustible source of human cortical 
neurons. Together with the discovery and application of recent advances in genome 
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editing, namely the transcription activator-like effector nuclease (TALEN) system and 
the clustered regularly interspaced short palindromic repeat (CRISPR) system, 
IPSCs provide an opportunity to generate transgenic, knock-in, and knock-out 
human neurons in a systematic way. As such, the focus of this work was centered 
around generating AD models in iPSCs to study two different mechanisms of AD 
pathogenesis: tau propagation and aggregation, and the mechanism of APP 
processing in isogenic FAD mutants. 
AD epidemiology and clinical presentation 
Dementia is classified as a syndrome with many causes, including AD, 
frontotemporal dementia (FTD), vascular or multi-infarct dementia, Parkinson’s 
disease, vitamin deficiency, and many more. The symptoms of dementia often 
involve loss of memory, language, problem solving, and personal independence. As 
the most common form of dementia, AD affects 5.5 million Americans and some 40 
million people worldwide (Alzheimer's Association, 2017; Scheltens et al., 2016). 
Age is the biggest risk factor for AD, as it affects one in 10 people over the age of 
65, and one in three over the age of 85 years old (Alzheimer's Association, 2017). 
As modern medicine continues to advance, human longevity concomitantly 
increases. As such, the proportion of our population over the age of 65 is steadily 
increasing, and is expected to rapidly expand in the coming decades as the first 
members of the baby boom generation turned 70 in 2016 (Alzheimer's Association, 
4 
2017). As a result, it is estimated that the number of people with AD will roughly 
triple by 2050 to almost 14 million Americans (Alzheimer's Association, 2017). 
Importantly, AD is the only disease in the list of top 10 causes of death that cannot 
be prevented or even slowed, as no disease modifying therapies have been 
approved to date, and perhaps more importantly, no clinical trials have shown even 
a hint of beneficial clinical effects. Therefore the financial burden of AD will continue 
to rise, from an estimated $259 billion in 2017, to an estimated $1.1 trillion in 2050, if 
effective therapies are not discovered (Alzheimer's Association, 2017). 
The clinical manifestations of AD are numerous and can vary from patient to 
patient. The typical presentation of AD is the insidious onset of memory loss in 
elderly patients over the age of 65, usually described as deficits in the ability to learn 
and make new memories. The disease then progresses, without pause, to impair 
executive function, language, and visuoconstructive abilities (i.e. the ability to 
organize spatial information), impairing activities of daily living and requiring round 
the clock care (American Psychiatric Association, 2013). In the final stages of the 
disease, motor control is also impaired, resulting in gait disturbances, dysphagia and 
incontinence, leaving the patient bedbound and completely incapable of taking care 
of themselves.  Finally, the most common cause of death in these patients is due to 
aspiration and subsequent pneumonia. 
Unfortunately, many of the symptoms of AD are shared among other 
neurocognitive disorders, such as Lewy body dementia and FTD. In addition, vitamin 
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B12 deficiency can present with similar symptoms. Therefore, an AD diagnosis 
requires a careful recounting of the patient’s medical history obtained from the 
patient, family and/or care givers to first rule out all other etiologies, making AD a 
diagnosis of exclusion (American Psychiatric Association, 2013). But even with 
history, physical and neurologic exams, AD can only be diagnosed as “probable” or 
“possible” in the clinical setting; post-mortem analysis is required to definitively 
diagnose AD based on the presence of distinct neuropathological features. 
Neuropathology of AD: Ab and tau 
AD is defined by the presence of key neuropathological findings, namely 
global brain atrophy, synapse loss, extracellular plaques composed of Ab (Tanzi et 
al., 1987), and intracellular tangles of tau (Grundke-Iqbal et al., 1986; Wischik et al., 
1988). Ab is derived from a series of cleavages of its precursor protein, APP (Figure 
1.1). APP is a ubiquitously expressed, single pass transmembrane protein that is 
initially cleaved by either the metalloprotease α-secretase, or the aspartyl protease 
b-secretase (BACE). Initial ectodomain shedding of APP by α-secretase commits 
APP towards the non-amyloidogenic pathway, as the ultimate products are soluble 
APPα (sAPPα) and P3, a soluble non-toxic byproduct of γ-secretase cleavage of the 
α-C-terminal fragment (α-CTF). On the other hand, initial cleavage by BACE 
commits APP to the generation of Aβ. 
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Cleavage of APP by BACE generates soluble APP-β (sAPPb) and a β-C-terminal 
fragment (β-CTF). Similar to α-CTF, b-CTF subsequently undergoes 
intramembranous proteolytic cleavage by g-secretase to release the APP 
intracellular domain (AICD) within the cell, and Ab fragments of various lengths into 
the extracellular space (Figure 1.2). g-secretase is a tetrameric protein complex 
Figure 1.1 Processing of APP. APP is a single pass transmembrane protein that 
undergoes a series of catalytic cleavages. In the non-amyloidogenic pathway, APP 
is initially cleaved by a-secretase, yielding sAPPa and a-CTF. g-secretase then 
cleaves the a-CTF to release the AICD and the soluble P3 fragment. The 
amyloidogenic pathway is initiated by cleavage of APP by BACE, producing sAPPb 
and b-CTF. g-secretase then utilizes the same mechanism used in the non-
amyloidogenic pathway to produce the AICD and Ab, which under pathogenic 
conditions aggregates and deposits as Ab plaques. 
7 
composed of a 1:1:1:1 ratio of the catalytic subunit, PSEN1 or PSEN2, nicastrin 
(NCT), anterior pharynx 1 (Aph1), and presenilin enhancer 2 (PEN2). g-secretase 
normally cleaves b-CTF with an initial endopeptidase cleavage between amino acids 
50/49 or amino acids 49/48, releasing an AICD of two different lengths. g-secretase 
then performs several successive tri- or tetra-peptide carboxypeptidase cleavages of 
the Ab protein fragment to ultimately yield either Ab of 38 (Ab38) or 40 (Ab40) amino 
acids (Takami et al., 2009). Normally, Ab is released as these shorter, soluble 
fragments, with Ab40 being the most predominant (Rogaev et al., 1995; Scheuner et 
al., 1996; Selkoe, 1996). Longer forms of Ab, like the 42 amino acid form (Ab42), are 
more prone to aggregation (Jarrett et al., 1993), and are the most abundant forms 
found in AD plaques (Iwatsubo et al., 1995), suggesting that Ab42 is more 
pathogenic. 
Under homeostatic conditions, Ab peptides are regularly cleared from the 
brain parenchyma (Castellano et al., 2011; Paresce et al., 1996; Selkoe, 2000; 
Wyss-Coray et al., 2003). However, under conditions where the production of longer 
Ab species is increased, or the clearance of Ab is reduced, there is an increase in 
the concentration of Ab, which facilitates oligomerization and fibrillization of Ab into 
plaques (Selkoe, 2000; Selkoe and Hardy, 2016). Nevertheless, three decades of 
research have failed to reveal the mechanism by which Ab promotes 
neurodegeneration, as well as its contribution to the clinical presentation of AD. 
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The second clinical hallmark of AD is the aggregation and 
hyperphosphorylation of the microtubule associated protein tau  (Grundke-Iqbal et 
al., 1986). Importantly, it was observed that the degree of NFT burden, not Ab, 
correlated with disease severity, implying a causal role for tau in the pathogenesis of 
AD (Braak and Braak, 1991). Tau is a cytosolic protein that binds to microtubules 
Figure 1.2 Processing of b-CTF by g-secretase. b-CTF is recognized and cleaved 
intramembraneously by the g-secretase complex. The catalytic component, PSEN1 
or PSEN2, cleaves b-CTF initially between amino acids 50/49 or 49/48. This 
endopeptidase activity commits b-CTF to the production of either Ab40 or Ab38 
respectively through a series of carboxypeptidase cleavages, removing 3 or 4 amino 
acids at a time. 
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and helps to facilitate their assembly (Weingarten et al., 1975). Microtubules are the 
major structural component of neuronal axons, serving as molecular highways on 
which many proteins and vesicles are trafficked, from cell body to synapse and vice 
versa. Tau helps to stabilize these microtubules and facilitate the transport of cargo 
along microtubules (Ebneth et al., 1998; Millecamps and Julien, 2013; Spires-Jones 
and Hyman, 2014). Tau is therefore normally distributed throughout axons of the 
central and peripheral nervous systems, with more limited expression in the cell 
bodies and dendrites. However, tau becomes hyperphosphorylated in AD, causing it 
to dissociate from microtubules, mislocalize to somatodendritic compartments, and 
aggregate intracellularly into fibrils and NFTs (Figure 1.3) (Götz and Ittner, 2008). 
Intracellular aggregation of hyperphosphorylated tau jeopardizes normal neuronal 
function by recruiting and sequestering functional tau, as well as other microtubule 
associated proteins (e.g. MAP1 and MAP2 (Alonso et al., 1997)), into these 
aggregates, thereby compromising normal microtubule function. The impaired 
function of microtubules disrupts the axonal integrity, leading to the degeneration of 
synapses, and ultimately of the neuron itself. However, the exact cellular 
mechanisms of how intracellular aggregation of tau causes neuronal degeneration 
remain unclear (Iqbal et al., 2015). 
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Figure 1.3 Tau pathology in AD. Tau normally binds and stabilizes microtubules in 
axons. In AD, tau becomes abnormally hyperphosphorylated. This facilitates 
dissociation from microtubules, oligomerization and aggregation of tau in the 
somatodendritic compartment. (Reprinted with permission from (Götz and Ittner, 
2008)) 
Genetics of AD and the Amyloid Cascade Hypothesis 
In 99% of AD cases, the disease occurs sporadically. This form of AD 
typically occurs late in life, with the earliest symptoms occurring almost always after 
the age of 65. The remaining 1% of AD patients inherit the disease in an autosomal 
dominant fashion. It was first suspected that AD could be inherited when it was 
recognized that patients with trisomy 21, or Downs Syndrome (DS), that survived 
into their fourth and fifth decades of life frequently developed AD (Masters et al., 
1985). In the years following, it was discovered that the major component of the 
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extracellular plaques in AD brains consisted of Ab, a degradation product of APP, 
which, interestingly, maps to chromosome 21 (Goldgaber et al., 1987; Kang et al., 
1987; Robakis et al., 1987; Roher et al., 1986; St George-Hyslop et al., 1987; Tanzi 
et al., 1987). Thus, genetic triplication of chromosome 21 in Downs Syndrome leads 
to over-production of APP and its byproducts, including Ab. It is thought that these 
elevated Ab levels cause an earlier age of onset in FAD than in their sporadic 
counterparts. Shortly thereafter, two families were reported to have a high incidence 
of an aggressive, AD like illness that occurred earlier in life, with an autosomal 
dominant pattern of inheritance (Goate et al., 1991). In these families, a missense 
mutation was mapped to APP on chromosome 21, providing the first direct link 
between APP and AD. 
These genetic findings, coupled with the characteristic histopathology of AD, 
gave APP processing a central role in the cause of both sporadic and familial AD. 
This view was reinforced with the discovery of mutations in two other genes, 
mapping to chromosome 14 and chromosome 1, that also caused FAD (Clark et al., 
1995; George-Hyslop et al., 1992; Levy-Lahad et al., 1995; Rogaev et al., 1995; 
Schellenberg et al., 1992; Van Broeckhoven et al., 1992). Though the function of 
these proteins were not initially known, it was soon shown that both genes were 
involved in the production of Ab (Citron et al., 1996; 1997; Klafki et al., 1996; Levitan 
et al., 1996; Li and Greenwald, 1996; Scheuner et al., 1996; Tischer and Cordell, 
1996). The genes, PSEN1 and PSEN2, encode the transmembrane proteins PSEN1 
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and PSEN2 (De Strooper et al., 1997), which are the catalytic components of the g-
secretase complex responsible for cleaving b-CTF to produce Ab (Figure 1.2) (De 
Strooper et al., 1998). In seminal work, these researchers were the first to 
demonstrate the disproportionate overproduction of Ab42 relative to Ab40 in these 
families. Further, it focused the field’s attention on the importance of APP processing 
in AD and, more specifically, on the production of longer Ab fragments.  These 
genetic findings bolstered support for Ab, specifically the overproduction of Ab, as a 
causal agent in the pathogenesis of FAD. 
In contrast to FAD, sporadic AD is much more common and presents later in 
life. Many risk factors for developing sporadic AD have been identified. The most 
important, and perhaps the most obvious risk factor for AD is age (American 
Psychiatric Association, 2013). There are, however, many other genetic risk factors 
that can potentially be used as targets for AD therapies. The greatest genetic risk 
factor that has been identified is the apolipoprotein E (APOE) genotype, with the 
APOE e4 allele conferring a 50% lifetime risk for developing AD in homozygotes, 
while the APOE e2 allele is considered to be protective against AD (Corder et al., 
1994; 1993; Scheltens et al., 2016; Strittmatter et al., 1993). APOE has several 
disparate roles, functioning in both the systemic circulation as well as in the brain. As 
it relates to AD, APOE has been shown to function in the clearance of Ab, with the 
APOE4 allele being less efficient in clearing Ab (Castellano et al., 2011). In addition 
to APOE, genome-wide association studies (GWAS) have identified several other 
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loci that are risk factors for the development of AD (Guerreiro and Hardy, 2014; 
Guerreiro et al., 2013). Many of the genes identified by these studies are involved in 
the clearance or metabolism of APP products (Guerreiro and Hardy, 2014), 
suggesting that sporadic AD may be a disease of reduced Ab clearance, rather than 
an increase in Ab production as in FAD (Mawuenyega et al., 2010). Importantly, both 
mechanisms result in a shared phenotype, specifically increased Ab levels in the 
brain. 
The finding that both sporadic and familial AD result in elevated Ab levels in 
the brain led to, and support, the “amyloid cascade hypothesis,” which postulates 
that a chronic imbalance between production and clearance of Ab leads to the 
deposition and accumulation of Ab plaques in the brain, and this gradual 
accumulation of plaques over many years ultimately leads to the pathologic changes 
that are characteristic of AD (Hardy and Higgins, 1992). Importantly, the hypothesis 
states that Ab is the initiating factor of AD, with all other pathological changes, 
including tau hyperphosphorylation and aggregation, occurring downstream of Ab. 
Evidence to support that Ab can induce toxicity upstream of tau was demonstrated 
when Ab oligomers induced neurodegeneration of mouse primary neuronal cultures, 
but failed to do so in neuronal cultures from tau knock-out mice (Rapoport et al., 
2002; Roberson et al., 2007). Ab has also been shown to induce tau phosphorylation 
(Jin et al., 2011) and promote synapse loss (Koffie et al., 2009), two major 
phenotypes observed in AD patients. Further, plaques of Ab induce microgliosis and 
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astrocytosis in their immediate area, tying Ab toxicity to inflammatory processes that 
have also been confirmed by GWAS studies. 
While the amyloid cascade hypothesis is supported by a large body of data, 
there are other pieces of evidence that bring the hypothesis into question. Perhaps 
the most compelling and intriguing evidence that argues against the amyloid 
cascade hypothesis is the regular observation of cognitively normal individuals that 
have a substantial amyloid plaque burden in the brain post-mortem (Davis et al., 
1999). This suggests that Ab deposits may not always be toxic and that AD is much 
more complex than a linear sequence of events that begins and ends with aberrant 
Ab homeostasis. Furthermore, patients with other forms of dementia, such as FTD, 
present with similar clinical symptoms, including NFTs and neurodegeneration, but 
have no evidence of Ab plaques in their brains (Dumanchin et al., 1998; Hong et al., 
1998; Hutton et al., 1998). As mutations in MAPT, the locus encoding the tau 
protein, are causal in FTD, it suggests that tau is sufficient induce 
neurodegeneration on its own, without an Ab trigger. These observations further 
highlight the complexity and our incomplete understanding of the underlying etiology 
of AD. 
Models of AD 
Since the discovery of familial mutations that cause AD and FTD, numerous 
animal and cell culture models have been developed to study these diseases. 
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Because there is no identifiable cause of sporadic AD, researchers have relied on 
these familial mutations to reveal mechanistic insights into these diseases in the 
hope that their findings will also be relevant for understanding and treating sporadic 
cases of AD. The most prominent, and perhaps most useful, models have been 
animal disease models, with transgenic mice leading the way. The study of 
transgenic mice has helped elucidate important disease mechanisms, including the 
role of PSEN1 in Ab production (De Strooper et al., 1998; Qian et al., 1998; 
Thinakaran et al., 1996). However, these animal models also have some major 
drawbacks. 
In order to be an effective tool for understanding disease mechanisms, it is 
imperative that the animals share the same, or similar, symptoms and pathologies to 
those observed in human patients. In the case of AD mouse models, the hallmarks 
of the disease that mice should exhibit include age-dependent deposition of Ab 
plaques and NFTs in the brain, neurodegeneration and impaired cognition. Because 
heterozygous carriers of mutations in APP, PSEN1 and PSEN2 are sufficient to 
cause AD, it is reasonable to expect that mice expressing a transgene of one of 
these disease-causing alleles would be sufficient to induce hallmarks of AD. 
However, this has not been the case for any FAD allele that has been expressed as 
a transgene in mice to date. For example, mice overexpressing mutant human APP 
(e.g. the APP Swedish mutation (APPswe)), develop age related Ab plaques, exhibit 
neuronal loss and cognitive impairment, but do not develop NTFs (Hall and 
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Roberson, 2012; Hsiao et al., 1996; Sturchler-Pierrat et al., 1997; Weggen and 
Beher, 2012). Similarly, in mice overexpressing mutant PSEN1 (e.g. M146V 
mutation), Ab levels in brain are elevated, specifically Ab42, however the mice do 
not develop plaques, NFTs or show cognitive deficits (Duff et al., 1996; Hall and 
Roberson, 2012; Holcomb et al., 1999). These shortcomings of mouse models may 
be attributable to differences between human and mouse genetics. In the case of 
PSEN1 models, human PSEN1 may process human APP differently than mouse 
APP, which differs by 17 amino acids, three of which are in the N-terminus of Ab 
(Hall and Roberson, 2012). Examples like this highlight the difficulties in modeling a 
uniquely human disease in an animal that fails to develop the disease on its own. 
Nevertheless, researchers eventually prevailed in developing a mouse model 
that recapitulates all the characteristics of AD. This required the expression of 
separate mutations in APP, PSEN1 and MAPT, and is known as the triple-transgenic 
mouse (3x-Tg) (Oddo et al., 2003). Notably, this mouse required the expression of a 
MAPT mutation that does not result in AD, but instead causes FTD (Hutton et al., 
1998). Furthermore, the 3x-Tg, as well as other AD mouse models with disease 
pathology, requires the massive overexpression of transgenes to observe relevant 
phenotypes. However, this is significantly different from the human condition, in 
which physiological expression of a single diseased allele is sufficient to cause the 
pathology and the disease. This illustrates not only the difficulties in establishing 
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animal models of AD, but also serves as a warning against using these animals to 
make concrete conclusions about the mechanisms that cause AD in humans. 
In addition to animal models, there has been considerable effort to generate 
cell culture models of AD. While these models cannot be used to study the complex 
behavioral deficits associated with AD, they have been instrumental in defining the 
mechanisms of Ab production and g-secretase function. Studies examining the 
function of g-secretase have been particularly insightful. Many of these models utilize 
stable overexpression of a FAD-causing PSEN1 mutation in non-neuronal cell lines 
(Figure 1.4). Often, these cell lines are in a background of a PSEN1/PSEN2-/- 
double-knockout, thereby conferring the ability to study the FAD mutant in isolation 
(Bentahir et al., 2006; Thinakaran et al., 1997; Walker et al., 2005; Weggen and 
Beher, 2012). However, this is another example of a departure from the diseased 
patient. FAD patients are heterozygous for the mutant allele, and therefore express 
WT and mutant PSEN1 at roughly equal levels, whereas these in vitro models only 
express the mutant allele. Furthermore, the diseased patient also expresses WT 
PSEN2, whereas the cell culture double-knockout model does not express PSEN2 
at all. While these models are extremely useful in understanding the mechanisms of 
action of WT and mutant PSENs in isolation, they may not reflect the true disease 
phenotypes experienced in a patient. 
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Figure 1.4 Cell culture models of PSEN1 mutations. A) FAD patients are 
heterozygous for PSEN1 (green) or PSEN2 (blue), expressing equal ratios of WT 
and mutant alleles (red). In most cell culture models, however, mutant PSEN1 
transgenes are B) stably overexpressed and are therefore express almost 100% 
mutant PSEN1, or C) in the case of the PSEN1/PSEN2 double knockout, 100% 
mutant PSEN1. 
19 
These shortcomings in disease models, however, do not call into question 
previous findings. Many of the observations from these models have been confirmed 
across numerous systems, and the mechanisms that have been elucidated and 
widely accepted as true. Instead, they simply call for the generation of newer models 
that better represent the physiologic conditions in diseased patients. This is 
especially critical as newer technologies are developed, such as the iPSC system, 
and genome editing techniques (TALEN and CRISPR). 
Induced pluripotent stem cells 
In 2006, Shinya Yamanaka and colleagues demonstrated that somatic cells, 
such as fibroblasts, could be reprogramed to an embryonic stem cell like state 
(Takahashi and Yamanaka, 2006). All that was required for this transformation was 
the introduction of four transcription factors, Oct4, Klf4, Sox2 and C-Myc, and the 
cell would express genes that promoted the dedifferentiation of somatic cells, and 
therefore resemble a stem cell. Like embryonic stem cells, these iPSCs are capable 
of limitless self-renewal, and importantly, can differentiate into all three germ layers: 
ectoderm, mesoderm and endoderm. These qualities earned these cells the title of 
induced pluripotent stem cells, capable of generating any cell type with the exception 
of placental and extraplacental tissue. This extraordinary technology earned Dr. 
Yamanaka a share of the 2012 Nobel Prize in Medicine. 
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With the advent of iPSC technology came many promises for the scientific 
community, including a better approach for modeling monogenetic diseases. 
Patients with disease causing mutations could now provide a skin biopsy that can be 
used to dedifferentiate their fibroblasts into iPSCs, thereby generating a cell 
repository for numerous patient iPSC lines that harbor various diseases-causing 
mutations. These lines could then be differentiated into their disease relevant cell 
types (e.g. human cortical neurons in FAD), studied for disease mechanisms, and 
used for pharmacological screens to identify drugs that may eventually be used to 
treat the diseased patient (Figure 1.5). Based on work in embryonic stem cells, 
cortical neuron differentiation protocols were quickly established for iPSCs, allowing 
for the reliable generation of human cortical neurons of both upper and lower cortical 
layers (Chambers et al., 2009) (Figure 1.6). 
21 
As a result, many different iPSC models for FAD models have been 
generated (Koch et al., 2012; Kondo et al., 2013; Muratore et al., 2014; Shi et al., 
2012a; Woodruff et al., 2013; Yagi et al., 2011; Yahata et al., 2011; Zhang et al., 
2014). However, the vast majority of these studies have compared phenotypes of 
patient derived iPSC lines to related or unrelated WT iPSC lines. While these can be 
considered appropriate control cell lines, differences in genetic heterogeneity and 
dedifferentiation can confound the interpretation of the data when comparing cell 
Figure 1.5 iPSC disease modeling. The introduction of four transcription factors, 
Oct4, Sox2, Klf4, and C-Myc, into any somatic cell of a human patient or healthy 
control, will convert it to an iPSC. This then allows for the generation of disease 
relevant cell types, such as cortical neurons in FAD, for the study of disease 
phenotypes in vitro. Discoveries made in vitro can then be translated into therapeutic 
strategies for patients affected by the disease. 
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lines from different people and therefore from different iPSC clones. This is crucially 
important when comparing subtle phenotypes, as slight differences in genetic 
background could potentially lead to false-positive, or false-negative interpretations 
of results. This highlights the need for isogenic control iPSC lines when comparing 
the effects of a single mutation. Fortunately, the advent of modern genome editing 
technology has made it possible to rapidly generate isogenic iPSCs. 
Figure 1.6: Differentiation of iPSCs into cortical neurons. A) Neurons derived 
from WT iPSCs and cultured until DIV64 express axonal markers of β-III tubulin 
(Tuj1) and the dendritic marker MAP2, as well as Nestin, an NPC marker. B) Longer 
maturation of neurons until DIV103 reveals neurons expressing upper (Satb2) and 
lower (CTIP2 and Tbr1) cortical layer markers, along with an extensive tau-positive 
axonal network. 
Genome editing with TALENs and CRISPR 
In the last decade, there have been major advances in the ability to efficiently 
edit the genome of human cells. Two of the tools commonly used for genome editing 
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are TALENs and CRISPR/Cas9. TALENs are naturally occurring proteins produced 
by the plant pathogen Xanthomonas spp. (Römer et al., 2007). These proteins are 
formed with a string of amino acid repeats that are engineered to specifically bind 
DNA sequences of the plant host in order to enhance the pathogen’s virulence 
(DeFrancesco, 2011). Once the amino acid code of TALENs was deduced (Boch et 
al., 2009; Moscou and Bogdanove, 2009), it was clear that these proteins could be 
engineered to target any DNA sequence in the genome by fusing TALENs to a DNA 
nuclease, such as FokI, to create a precisely targeted double stranded break (DSB) 
(Figure 1.7A). In fact, it wasn’t long before this system was adapted to human 
iPSCs (Hockemeyer et al., 2011), allowing for the generation of transgenic, 
knockout, or knock-in iPSCs by taking advantage of the host cell’s DNA repair 
system (Figure 1.7A and B). 
At around the same time, the CRISPR/Cas9 genome editing technology was 
being developed from the bacterial and archaeal adaptive immune system (Horvath 
and Barrangou, 2010). The CRISPR/Cas9 system uses a strand of RNA to bind to a 
complementary strand of DNA from an invading pathogen, such as a bacteriophage, 
to guide the Cas9 complex, a large protein complex that typically has endonuclease 
activity, to silence the invading organism and protect the host. Like TALENs, this 
system was quickly adapted for mammalian cells to perform RNA guided (gRNA) 
DNA repair or gene editing using the endogenous DNA DSB repair machinery (Hsu 
et al., 2014; Jinek et al., 2012; Mali et al., 2013). Typically, DSBs generated by 
24 
CRISPR/Cas9 are repaired by non-homologous end joining (Figure 1.7B) (NHEJ), 
which repairs the break by the insertion or deletion (indel) of random nucleotides, 
often resulting in frameshift mutations (Hsu et al., 2014). This provides an easy and 
efficient way of generating knockouts of a target gene, but generating knock-in 
mutations pose a more difficult task. 
Figure 1.7. Genome editing with TALENs and CRISPR/Cas9. Schematics 
representing the mechanisms of genome editing by TALENs (A and C) and 
CRISPR/Cas9 (B and D). Both techniques generate a DSB at the targeted locus, 
which is predominantly edited by the random insertion or deletions of nucleotides via 
NHEJ (A and B). In rare instances, a repair template is used to facilitate HDR of the 
locus. 
In order to generate knock-in mutations, a cell must undergo homology 
directed repair (HDR), which utilizes a DNA template to guide the accurate repair 
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(Figure 1.7B and D) (Mali et al., 2013). However, this process is very inefficient and 
imprecise (Canver et al., 2014; Cong et al., 2013; Dow et al., 2015; Platt et al., 2014; 
Yang et al., 2013). Fortunately, our laboratory developed a system that enhances 
both the efficiency and accuracy of HDR to introduce the knock-in of specific point 
mutations using a single stranded oligo DNA nucleotide (ssODN) (Kwart et al., 2017; 
Paquet et al., 2016). The method takes advantage of silent mutations that block the 
proto-spacer adjacent motif (PAM), which consists of a three base-pair (bp) NGG 
sequence, to increase the accuracy of editing by preventing Cas9 from re-cutting a 
locus that has already been targeted and repaired. Thus, our method reduces the 
rate of NHEJ, thereby increasing the accuracy of editing and facilitating the rapid 
generation of isogenic mutant iPSC lines for modeling of human diseases. 
Perspective and overview of thesis project 
The work presented in this thesis project originally began with the goal of 
elucidating the mechanism of tau spreading in iPSC-derived human cortical neurons. 
Previous studies had shown that tau could move from neuron to neuron along 
anatomically connected pathways in transgenic mice. These mice regionally 
expressed a human tau transgene in the entorhinal cortex, and demonstrated age-
dependent dissemination of human tau throughout the cortex along the perforant 
pathway, suggesting trans-synaptic spreading (Liu et al., 2012). While these in vivo 
data are compelling, it was still unclear whether tau was moving from inside one cell 
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to inside another, as some studies suggested that the promoter used to restrict 
localization of tau to the entorhinal cortex was leaky (Yetman et al., 2015). In 
addition, it has been shown in vitro that aggregates of tau can induce normal soluble 
tau to misfold, a mechanism similar to that seen in prion disease (Crutzfeld-Jacob 
disease) (Guo and Lee, 2011; Kfoury et al., 2012; Sanders et al., 2014). This 
provides an important link between spreading of tau and disease progression, as 
aggregates of tau that gain access to a previously healthy neuron can induce 
aggregation and disease in distant regions of the brain. As such, we aimed to 
develop an in vitro model to not only faithfully track tau as it moved from donor to 
recipient neurons, but also to aid in elucidating the mechanism of tau transfer. 
Importantly, this model system would be the first to use human cortical neurons, the 
disease relevant cell type in AD, and understanding this disease mechanism in a 
physiologically relevant context would potentially identify targets for novel drug 
development. 
In addition to the tau spreading project I originally proposed, I also undertook 
a second project in the last year of my thesis work. As will be discussed in more 
detail below, we found that tau does in fact spread, however to no greater extent 
than the cytosolic fluorophore of our control cell line. This suggested that cellular 
transfer tau was mediated by a mechanism that is not specific to tau. Seeing as this 
result would require the generation of numerous additional control cell lines 
expressing proteins of various size, conformation, charge or polarity, and therefore 
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many more years than was possible, we decided to investigate a second AD disease 
mechanism that had previously been demonstrated in the lab by Dylan Kwart. Dylan 
had shown that introducing the FAD PSEN1 mutation, M146V, into iPSCs via 
CRISPR/Cas9 genome editing results in an increase in the ratio of Ab42:40 when 
differentiated into cortical neurons, a finding that has been repeatedly observed in 
vivo and in vitro. Since there has been significant debate in the field surrounding 
whether PSEN1 FAD mutations are gain-of-function or loss-of-function, we decided 
to focus on PSEN1 and its role in Ab production by knocking in several different FAD 
mutations into WT iPSCs to create a series of isogenic lines. Importantly, doing this 
in iPSCs via knock-in mutation of the endogenous locus allowed us to study the 
effects of these mutations in clinically relevant human cell types, and at physiological 
levels of expression, therefore establishing a system that is much more closely 
relatable to the disease in humans. 
I have completed two fairly unrelated projects; both required a significant 
amount of cell line generation via genome editing, so I will devote all of Chapter 2 
describing the generation of the various iPSC lines for both projects. For the tau 
spreading project, TALENs were used to target the genomic safe harbor locus, 
AAVS1, where I inserted a doxycycline inducible promoter transgenic system to 
control the expression of various fluorescently labeled tau transgenes. To generate 
recipient cell lines, a second genomic safe harbor was targeted with TALENs, the 
H11 locus, and a constitutively expressed membrane anchored YFP (memYFP) was 
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inserted. For the PSEN1 project, CRISPR/Cas9 was used to knock-in four separate 
FAD mutations, M146V, L166P, M233L and A246E, in either heterozygous or 
homozygous form. 
In Chapter 3, I will focus on the tau spreading project. In contrast to previous 
studies, I will show that tau does in fact spread from cell to cell in this system, 
however it does not spread in a manner specific to tau, as the donor control cell line, 
expressing just the mCherry fluorophore, spread just as efficiently as the tau donor. I 
then wanted to ask what the consequence of spreading is in human iPSC-derived 
cortical neurons. Namely, can tau induce aggregation of normal tau in human 
cortical neurons? To answer this, I generated recombinant tau aggregates with the 
assistance of my Committee Member, Dr. David Eliezer. These aggregates were 
able to induce the aggregation of tau in a HEK293T biosensor system designed to 
measure the seeding activity of tau aggregates using immunofluorescence or 
fluorescence resonance energy transfer (FRET) (Holmes et al., 2014). However, 
when these aggregates were added to our human cortical neurons, we observed no 
ability to seed and induce aggregation of healthy tau. 
Chapter 4 will focus on the PSEN1 project, which aimed to describe the 
changes in Ab production resulting from FAD mutations in PSEN1. I found that 
mutations in PSEN1 resulted in a decrease in Ab40 and Ab38, and an increase in 
Ab42. Importantly, in heterozygous mutants, the total Ab remained relatively 
unchanged, while in homozygous mutants, Ab was decreased. These data suggest 
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that PSEN1 mutations are partial loss of function, specifically altering the last 
cleavage of Ab.  
In Chapter 5, I will conclude this thesis with a general discussion of the 
implications of the results from each of these projects. In addition, I will provide 
suggestions for future work for both of these projects. 
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CHAPTER II: GENOME EDITING AND CELL LINE GENERATION 
Donor and recipient cell lines for tau spreading 
Rationale 
In order to study the mechanisms that mediate spreading of tau between 
human neurons, we set forth to establish an in vitro system with two main features: 
1) the transfer of tau would readily and reproducibly propagate from neuron to
neuron, and 2) propagated tau is distinguishable from endogenous tau in recipient 
neurons. Such a model would provide a system to quantitatively assess the 
spreading of tau between cells as well as probe and manipulate the cellular 
pathways that mediate tau transmissions. To distinguish between endogenous and 
transmitted tau, the cells expressing tau designated to spread, or “donor” cell lines, 
must express a unique species of tau from the “recipient” cell lines. This can be 
accomplished in a variety of ways, including tagging tau with either a fluorophore, 
like mCherry or GFP, or with a small polypeptide protein tag, like a FLAG-tag or His-
tag. Another possibility is to utilize tau knockout recipient cells lines, such that only 
the donor cell line only express tau. With these considerations in mind, we decided 
to establish a system in which the donor cells expressed tau with an N-terminal 
mCherry tag. Because tau is only expressed in neurons, we thought it necessary 
that the mCherry tagged tau be under the control of an inducible promotor, namely 
the Tet-On 3G inducible expression system so that tau was not improperly 
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expressed in iPSCs or neural precursors (NPCs) (González et al., 2014; Gossen 
and Bujard, 1992). For the recipient cell lines, we generated a cell line that 
constitutively expressed a membrane anchored YFP (memYFP). 
Recipient Cell Line 
Our initial efforts of genome editing utilized a method that was previously 
reported to faithfully insert transgenes of interest into iPSCs at a safe, intergenic, 
and transcriptionally active locus on chromosome 22 (H11 locus) (Zhu et al., 2013). 
This method was originally developed for introducing transgenes into iPSCs utilizing 
TALEN mediated HDR. Specifically, the cassette, or “landing pad” consists of a 
neomycin resistance and memYFP gene, and is flanked by two attachment sites 
(attP) for the integrases phiC31 and Bxb1. These integrase attachment sites allow 
for the introduction of a second donor cassette expressing a gene of interest,
thereby facilitating the exchange by way of dual cassette integrase exchange (DICE) 
(Figure 2.1A). For the purposes of this work, we only used the landing pad to 
express memYFP in order to generate the recipient cell line (Table 2.1). 
To generate our iPSC lines, WT iPSCs were co-electroporated with the 
landing pad and TALEN pair, then allowed to recover. Next, electroporated iPSCs 
were serially diluted to plate them as single cells, and neomycin (G418) was 
introduced for one week to select for clonal cell lines that successfully integrated the 
landing pad into the H11 locus. Surviving clonal colonies were expanded and then 
were manually picked into individual wells of a 96-well plate lined with MEFs. Clones 
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that had irregular or low expression of memYFP were excluded. The clones were 
then analyzed for the correct incorporation of the landing pad into the H11 locus by 
PCR (Figure 2.1B). Southern blot was used to confirm a single incorporation of the 
landing pad (Figure 2.1C). Cell lines were next analyzed by karyotyping, confirming 
that they lacked any chromosomal abnormalities (Figure 2.1D). Finally, these lines 
were also analyzed for pluripotency by immunocytochemistry using the pluripotency 
markers, Oct4, Tra-1-60, SSEA4 and Nanog (Figure 2.1E). 
Table 2.1: Tau spreading cell lines. List of donor and recipient cell lines generated 
for studying tau spreading 
Donor Cell Lines 
# Transgene Promoter Tag Selection Locus Parental Cell line 
1 mCherry 
TRE mCherry Puro/Neo AAVS1 Tau Knock-out 
2 FL - WT 
3 FL – P301L 
4 RD - WT 
5 RD – P301L 
Recipient Cell Lines 
6 memYFP CAG None Neo H11 WT 
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Figure 2.1: Generation of recipient cell line. A) Schematic of targeting and 
integration of the landing pad to generate recipient cell lines. B) PCR of genomic 
DNA to screen for heterozygous integration of the landing pad. Each genomic DNA 
PCR was amplified twice for the endogenous allele (WT-594bp) and the allele 
containing the integrated landing pad (LP-617bp) in control (CTL) and WT. C) 
Southern Blot of HindIII digested genomic DNAs with probe targeting the memYFP 
transgene. Arrow indicates expected band of 9.8kb. D) Karyotypye of clone E3 
selected for further analysis. E) Assessment of pluripotency markers Oct4, Tra-1-60, 
SSEA4 and Nanog by immunofluorescence. 
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Donor Cell Lines 
For the generation of the donor cell lines harboring an inducible tagged tau 
transgene, we turned to a second genomic safe harbor, AAVS1, that had also been 
previously published (González et al., 2014; Hockemeyer et al., 2011; 2009). This 
system utilizes bi-allelic introduction of a doxycycline inducible system (Figure 2.2A). 
Briefly, a TALEN pair targeting the first intron of the PPP1R12C gene was 
introduced by electroporation into WT iPSCs along with two donor cassettes. The 
first of these cassettes contains a splice acceptor (SA) site, followed by a P2A 
ribosomal slip sequence and a puromycin resistance gene. On the opposite end of 
the cassette and inverted was the tetracycline response element (TRE), driving 
expression of mCherry tagged tau. Four separate cassettes expressing four different 
tau transgenes were cloned and introduced into iPSCs separately. In addition, we 
generated a control cell line that would express mCherry alone (Table 2.1). The four 
tau transgenic lines comprise two complementary pairs that would allow us to 
compare differences in the spreading or aggregation of wild-type tau vs tau 
containing a FTD-causing mutation (Dumanchin et al., 1998; Hutton et al., 1998).
The first pair of transgenic lines express either the full length (FL) WT tau containing 
both N-terminal inserts (2N) and all four repeat domains (4R) or the FL 2N4R FAD 
mutant P301L tau, which has been shown to promote tau aggregation (Barghorn et 
al., 2000; Bergen et al., 2001; Fischer et al., 2007). The second pair of tau 
transgenic lines express only the repeat domains (RD) of tau, exons 9 through 12, in 
either the WT or P301L mutant form. These RDs form the microtubule binding 
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domains of tau, and are a major component of NFTs (Wischik et al., 1988). 
Prolonged overexpression of FL tau can be toxic in some cell models, but the RD 
form has been shown to be stable and propagate through numerous passages in a 
HEK293 model in vitro (Sanders et al., 2014).
The second cassette contains the same SA-P2A, but is followed by a 
neomycin resistance gene. Additionally, a tetracycline transactivator protein gene is 
constitutively expressed (Figure 2.2A). Upon addition of 5µg/mL of doxycycline, the 
transactivator binds to the TRE and initiates transcription of the mCherry tagged tau 
transgenes (Figure 2.2B). 
All tau transgenic cell lines were generated in the background of a tau knock-
out cell line that had been generated by Dominik Paquet, a post-doc in the Tessier-
Lavigne Lab. The rationale of this approach was that it would overcome any 
confounding effects that endogenous expression of tau might have on our analysis 
of spreading of transgenic tau. After generating these donor cell lines, I differentiated 
two different inducible cell lines, the mCherry control and the RD-WT, and treated 
them with and without 5μg/mL of doxycycline for 7 days and examined the 
expression of the inducible transgenes by Western blot. Unfortunately, there was a 
troublesome observation. An antibody recognizing total tau (K9JA) revealed a faint, 
slightly truncated form of tau when compared to the WT (Figure 2.2C, arrowhead). 
To confirm the specificity of this band, I tested three other monoclonal antibodies 
against phosphorylated epitopes of tau, which recognized the same band, indicating 
that the knock-out line was not a true null (Figure 2.2D). 
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Figure 2.2. Inducible tau cell line characterization. A) Schematic for bi-allelic 
targeting of the AAVS1 locus for the generation of Tet-On inducible donor cell lines. 
B) Induction of expression of mCherry and mCherry:FL-WT tau in tau KO iPS cells
after selection with neomycin and puromycin with 5μg/mL doxycycline for 16 hours. 
Shown is the live fluoresence of mCherry C) Western blot of WT and inducible donor 
cell lines (KO background) for total tau. Arrowheads indicate the truncated form of 
tau detected in the “KO.” D) Western blot of WT and KO cell lines blotted with three 
monoclonal antibodies to separate epitopes of tau. E) WT of inducible donor cell 
lines with and without doxycycline induction for 7d at 5ug/mL. F) Representative 
pluripotency staining for Tra-1-60, Oct4, Nanog, and SSEA4 in mCherry tagged FL-
WT tau iPSCs. G) Normal karyotype for mCherry tagged FL-WT tau iPSCs. 
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While this was a troubling finding, the lines that I had generated in this 
background were still useful since they were still able to induce expression of the 
transgenic tau, without any leakiness of the promoter system (Figure 2.2E). Further 
quality control analysis revealed that these lines also maintained their pluripotency 
markers after genome editing and clonal expansion (Figure 2.2F), and also 
displayed a normal karyotype (Figure 2.2G). This concluded the TALEN genome 
editing for the generation of iPSC lines expressing inducible fluorescently tagged tau 
donor cell lines, and recipient cell lines with fluorescently labeled plasma 
membranes. 
Generation of isogenic FAD PSEN1 mutant iPSCs 
Rationale 
In this second iPSC model, we aimed to generate a series of PSEN1 
mutations across isogenic iPSC lines to better characterize the mechanism of Ab 
production by PSEN1. Previous studies had used a variety of model systems, 
including transgenic mice, stable cell lines, and transient transfection and 
overexpression in stable cell lines in order to study the effects of PSEN1 mutations 
on Ab production. However, very few of these models utilize physiological levels of 
expression of both substrate, APP, and enzyme, PSEN1 or PSEN2 and the other 
functional components of g-secretase, Aph1, PEN2 and NCT. Furthermore, these 
models have not studied these mechanisms in human cortical neurons, the disease 
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relevant cell type in AD. Therefore, we utilized WT human iPSCs to knock-in four 
FAD PSEN1 mutations, M146V, L166P, M233L, and A246E, at the endogenous 
PSEN1 locus using CRISPR/Cas9 mediated HDR. Because all these lines were 
generated from the same WT iPSC parental cell line, the mutant lines are isogenic, 
which allows for a cleaner interpretation of the results as genetic heterogeneity is 
ruled out. From these iPSC lines, human cortical neurons would be generated to 
characterize differences in Ab production between WT and mutants, as well as any 
other changes in enzymatic activity that these mutants might have on substrates 
other than b-CTF. 
CRISPR gRNA design and HDR templates 
There are more than 200 mutations in PSEN1 that cause FAD (alzforum.org). 
To design a manageable and representative study, we had to determine the number 
and identity of PSEN1 mutations that would yield the most meaningful results. We 
initially selected 10 mutations to investigate, but due to limitations of the 
CRISPR/Cas9 system, we were only able to successfully target four of these loci. 
The limitations included the availability of NGG sequences that were in close 
proximity to the FAD mutations, low activity of gRNAs, and the sheer volume of cell 
culture work involved in generating a single mutant iPSC line. In the end, we 
introduced and studied four FAD PSEN1 mutations: M146V, L166P, M233L, and 
A246E (Table 2.2). 
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Table 2.2. PSEN1 cell lines. List of WT and PSEN1 mutant isogenic iPSC cell lines. 
Mutation Line ID Genotype Karyotype 
WT A5 WT Normal 
L166P 
L9 Homo Normal 
L11 Het Abnormal 
M146V M1 Homo Normal M5 Homo Normal 
M233L ML5 Het Normal 
A246E A3 Het Normal A4 Het/Ind Normal 
To introduce these mutations, we utilized a commonly used online tool to 
identify and generate gRNAs from the Zhang Lab (crispr.mit.edu). This tool analyzes 
the target sequence of interest for the presence of NGGs, and then generates a 
report for each gRNA, giving it a score based on the potential for a given gRNA to 
have off-target effects due to sequence similarity. gRNAs were selected based on 
their given score, as well as their proximity to the desired mutation. Our lab 
previously showed a monotonic relationship between the distance of the CRISPR 
cut site and mutation incorporation, with shorter cut-to-mutation distances being 
more favorable for mutation incorporation (Paquet et al., 2016). As such, we choose 
gRNAs cut-to-mutation distances of 10 base pairs (bp) or less. gRNAs used for each 
mutation are listed in Table 2.3. 
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Table 2.3. gRNAs targeting PSEN1 mutant loci. 
locus gRNA sequence* 
M146V 6 GTTGTCATGACTATCCTCCTGG 
L166P 10 GAGATGATATAATAAGCCAGG 
M233L 18 GATTAGTGCCCTCATGGCCCTGG 
A246E 17 GATGGACTGCGTGGCTCATCTTGG 
* G = added for use with pMLM3636,
green = NGG 
For each mutation, an HDR template was designed with two important 
qualities in mind. First, each single stranded oligonucleotide (ssODN) template 
needed to have a silent PAM blocking mutation to abolish the NGG sequence, 
rendering that locus unrecognizable by Cas9 after successful HDR. To facilitate 
screening of clones, the PAM blocking mutations are designed to introduce, or 
abolish, an endonuclease recognition site to facilitate the rapid screening of 
hundreds of individual clones by restriction fragment length polymorphism (RFLP) 
assays. Secondly, the ssODNs must also incorporate the mutation of interest. 
Because we were interested in generating heterozygous clones in order to more 
accurately model FAD, additional factors needed to be taken into account because 
generating heterozygous clones is much more inefficient than generating 
homozygous clones (Paquet et al., 2016). To increase the odds of obtaining 
heterozygous clones, we created two separate ssODN templates, both harboring the 
PAM blocking silent mutation, and one template containing the pathogenic mutation, 
while the second template remained WT at the pathogenic mutation site. By mixing 
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these two ssODNs together (1:1 ratio of WT to mutant template), the rate of 
heterozygous clone generation increases as both templates could in theory be used 
for each allele (Paquet et al., 2016). A list of repair templates, with pathogenic and 
PAM blocking mutations, are annotated along with the RFLP enzyme used for clone 
screening in Table 2.4. 
Table 2.4. HDR templates. HDR ssODN templates for each mutation, as well as 
each enzyme used for RFLP analysis. 
Clone generation and quality control 
Generation of single cell iPSC clones requires a series of steps. First, the WT 
parental iPSC line is grown without MEF feeders for 24-48 hours until roughly 60-
70% confluent. These cells are then collected and electroporated with plasmids that 
express GFP and Cas9, and the gRNA. In addition, the WT and mutant ssODN 
repair templates are also mixed with the plasmids for electroporation. After 
electroporating 2 million iPSCs per reaction, with at least four to six reactions per 
electroporation totaling 8 to 12 million cells, the iPSCs are allowed to recover for two 
days to allow for GFP expression. GFP positive cells (GFP+) are then sorted by 
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fluorescence activated cell sorting (FACS) to select for GFP+ cells, which also 
express Cas9. The GFP positive cells are sorted into two groups, GFPhi and GFPlow, 
based the level of expression of GFP (and therefore Cas9) (Figure 2.3). 
Once sorted, iPSCs expressing Cas9 are then plated as single cells onto 
10cm dishes with MEF feeders. The cells are then allowed to grow into individual 
colonies for 12-16 days, or until the colonies are large enough to be manually picked 
off the plate and placed into individual 96-well plates with MEFs. After allowing the 
isolated clones to grow until confluent, they are passaged and replicated once more 
into 96-well plates. The remaining cells are then harvested for analysis of mutation 
incorporation. 
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Figure 2.3. FACS of GFP+ iPSCs into GFPhi and GFPlow subpopulations. Shown 
is a representative FACS sort for a given electroporation. iPSCs are sorted using 
DAPI dead cell exclusion, and subsequently gated for live single cells. Gates are 
then drawn to isolate two subpopulations of GFP+ cells, GFPhi and GFPlow. These 
populations are sorted into individual tubes for subsequent plating as single cells. 
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The 96-well plates containing the leftover cell suspension are centrifuged to 
bring the cells to the bottom of the plate, at which point the cells are lysed for the 
isolation of genomic DNA (gDNA). Once the gDNA is purified, the targeted locus is 
amplified by PCR and the PCR products are digested with the restriction 
endonuclease to assess the presence or absence of the PAM-blocking mutation. 
Restriction fragment length polymorphisms (RFLP) fragments were then run on an 
agarose gel (Figure 2.4), and clones that were homozygous for the PAM blocking 
mutation were further analyzed by Sanger sequencing to look for the introduction of 
the pathogenic mutation. Cell lines that demonstrated the presence of homozygous 
PAM blocking silent mutations, without indels, and WT, heterozygous, or 
homozygous alleles at the pathogenic mutation site were subsequently expanded for 
further quality control. 
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Figure 2.4. Representative RFLP screen from single experiment. Shown is a 
representative digest of roughly 300 individual clones from a single editing 
experiment. Red boxes show homozygous PAM blocking mutation integration, 
Green boxes show heterozygous PAM blocking integration, while Blue boxes 
demonstrate aberrant editing. 
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Figure 2.5. Edited iPSC lines quality control. A) Sanger sequencing traces, B) 
karyotype, and C) pluripotency staining for all edited lines. Red boxes highlight PAM 
blocking mutations, blue boxes highlight pathogenic mutations. 
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Each cell line that possessed an accurate editing event was then subject to a 
series of quality control measures, including a copy-number variant (CNV) assay to 
quickly determine the copy number of chromosome 20. Trisomy 20 is a common 
occurrence in iPSCs as it provides a growth advantage (Gaztelumendi and Nogués, 
2014; Lefort et al., 2008), and is a phenomenon that our lab frequently observes with 
our WT iPSC line. Unfortunately, the genome editing events described here were not 
immune to aneuploidy, as numerous cell lines with accurate HDR exhibited trisomy 
20. In addition, we occasionally lost cell lines to other aneuploidies, such as trisomy
1 or trisomy 12 upon karyotype testing. However, we were still able to generate 
several mutant and edited WT (harboring the PAM blocking silent mutation, but WT 
at the pathogenic mutation locus), that had normal karyotypes, and maintained 
pluripotency markers (Figure 2.5). Several cell lines unfortunately had accurate 
editing and normal karyotype, but did not differentiate well into neurons. Oftentimes 
these cells preferentially differentiated into glial-like cells instead of neurons, and 
were therefore eliminated from further analysis. Of note, one cell line with the L166P 
heterozygous mutation was trisomy 17, but happened to differentiate into neurons 
quite well. This cell line will be included in the analysis in Chapter 4, however this 
caveat should be considered when interpreting the data, and will be noted 
throughout the analysis. 
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CHAPTER III: Tau non-specifically transfers from donor to recipient 
neuron in vitro via macropinocytosis 
Background and rationale 
Tau pathology closely correlates with disease severity in AD patients (Arnold 
et al., 1991; Braak and Braak, 1991; Braak et al., 2011). As AD progresses, 
neurofibrillary inclusions, initially confined to a local region in the entorhinal cortex, 
spread to distant regions of the brain along anatomically connected pathways. This 
suggests that tau could propagate from neuron to neuron, effectively spreading the 
pathology to previously healthy regions of the brain and promoting disease 
progression. 
As a result, there have been a series of studies aimed at showing that tau 
does in fact propagate. However, these studies have been restricted to non-human 
cell lines (Frost et al., 2009a; Holmes et al., 2013), human non-neuronal cell lines 
(Holmes et al., 2013; Kfoury et al., 2012; Michel et al., 2014; Sanders et al., 2014), 
and transgenic mice (Clavaguera et al., 2009; de Calignon et al., 2012; Dujardin et 
al., 2014b; Iba et al., 2013; Liu et al., 2012; Sanders et al., 2014; Yanamandra et al., 
2013). Similar results have recently been published for other neurodegenerative 
proteinopathies, demonstrating that α-synuclein and huntingtin can spread from 
neuron to neuron in Parkinson’s (Luk et al., 2012) and Huntington’s (Pecho-
Vrieseling et al., 2014) disease respectively. This supports the idea that pathologic 
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protein entities like α-synuclein, huntingtin, and tau can spread within the brain and 
contribute to disease progression. As such, these processes could provide a 
pharmacological target by therapeutically neutralizing the toxic species or the 
propagation pathways that spread these species to healthy brain regions. Indeed, a 
number of groups have attempted to elucidate the cellular mechanisms that underlie 
tau spreading (Chai et al., 2012; Dujardin et al., 2014b; 2014a; Holmes et al., 2013; 
Karch et al., 2012; Lee et al., 2012; Mohamed et al., 2014; Pooler et al., 2013; 
Saman et al., 2012; 2014). However, these studies have failed to agree on the 
pathway(s) that mediate the exit and entry of tau from the donor to the recipient cell 
in the context of disease. Mechanisms of tau secretion that have thus far been 
proposed include vesicle associated (exosomal) release (Kim et al., 2010a; 2010b; 
Lee et al., 2012; Saman et al., 2012; 2014), non-vesicular (“unconventional”) release 
(Chai et al., 2012), and synapse mediated release (Pooler et al., 2013). Fewer 
studies have attempted to characterize tau uptake, but different mechanisms have 
been proposed including the involvement of an active endocytic process (Frost et al., 
2009b; Guo and Lee, 2011; Wu et al., 2013), possibly mediated by heparan sulfate 
proteoglycan (HSPG) dependent macropinocytosis (Holmes et al., 2013). 
Nevertheless, these studies were all executed in model systems that significantly 
differ from disease relevant human cortical neurons. It is, therefore, still unclear 
whether these results translate well to humans. 
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We sought to provide better insights into the mechanism of tau spreading by 
generating a transgenic iPSC model system that will allow for the tracking of tau 
between iPSC-derived human cortical neurons. Our goal was to faithfully observe 
tau spreading using human cortical neurons, and to then elucidate the mechanism 
using pharmacological intervention to characterize the several cellular processes 
involved in the release and uptake of tau. 
Preliminary studies in a human-mouse co-culture system highlight the need 
for non-physiologic conditions 
During my rotation project, I developed a co-culture system utilizing WT 
human cortical neurons and mouse hippocampal neurons to study the transfer of tau 
between these neurons. The rationale behind this experiment was that human and 
mouse tau would be readily distinguishable from each other by taking advantage of 
human and murine specific tau antibodies (Kosik et al., 1989). Furthermore, 
transgenic mice expressing a ubiquitous GFP (Giel-Moloney et al., 2007) were 
readily available in the lab. After optimizing the conditions for co-culturing mouse 
hippocampal neurons and human cortical neurons, I analyzed three-week-old 
neurons by immunofluorescence, using a human specific tau antibody (HT7), 
specifically looking for the presence of human tau within GFP+ mouse hippocampal 
neurons (Figure 3.1A and B). However, as these cells expressed cytosolic GFP, and 
did not label the plasma membrane, it proved difficult to distinguish intracellular and 
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extracellular compartments, preventing faithful determination of tau spreading. To 
circumvent this, we next utilized non-transgenic WT mice, and labeled mouse 
hippocampal neurons with an antibody to the murine specific neuronal cell surface 
marker L1 (N-CAM L1) (Lindner et al., 1983). Though I was able to distinguish the 
recipient cell border, I still failed to observe sufficient numbers of human tau entities 
within recipient mouse neurons, likely due to the low expression of tau in the donor 
cells (Figure 3.1C and D). 
Lessons learned from these preliminary experiments using human-mouse co-
cultures guided the direction of my research proposal, leading to the establishment 
of the donor/recipient co-culture system described in Chapter 2. This system uses a 
dox-inducible overexpression system to control the expression of fluorescently 
labeled tau transgenes. We turned to overexpression with the hope that increasing 
the protein levels of tau, so that we might increase the limit of detection of donor tau 
by immunofluorescence. Furthermore, it has been suggested that tau transfers 
trans-synaptically (Liu et al., 2012; Pooler et al., 2013), so we decided that an all 
human system would increase our chance of observing tau spread, as there was no 
evidence or guarantee that human and mouse neurons would form functional 
synapses between each other. 
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Figure 3.1: Human donor and mouse recipient co-culture model. Human iPSC-
derived cortical neurons were co-cultured with mouse hippocampal neurons from 
either ROSA26-eGFP mice (A, B), or CD1 WT mice (C, D). A and C represent two-
dimensional images of mouse, human and co-cultures B and D are representative 
orthogonal views of confocal images of co-cultures showing an optical plane on the 
level of mouse cell bodies. All cultures were stained with antibodies against human 
tau HT7, and either GFP (A, B) or L1 (C, D).  
55 
Alternative approaches to studying tau spreading 
Concurrent with our genome editing efforts, we decided it would be prudent to 
consider alternative experimental paradigms to examine spreading. Because our lab 
has effectively used lentivirus delivery systems to overexpress transgenes as well as 
shRNAs in mouse DRGs to elucidate mechanisms of neurodegeneration, we 
decided to try using lentivirus to overexpress mCherry tagged tau transgenes into 
WT, human cortical neurons. For this purpose, a series of viruses that express GFP 
followed by a P2A sequence and the mCherry tagged tau transgenes were 
generated. The goal of these lentiviral experiments was to infect neurons at a low 
multiplicity of infection (MOI) such that only about half of the neurons are infected. 
The infected neurons would then be doubled labeled with GFP and mCherry, while 
the uninfected neurons would serve as unlabeled recipient cells. Should spreading 
of tau occur, it could be visualized as mCherry single positive neurons (Figure 
3.2A). 
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Figure 3.2: Lentiviral over-expression of tau. A) Schematic of a neuron 
infected with a lentivirus expressing a GFP-P2A-mCherry:Tau (Yellow), with 
tau spreading to an uninfected, unlabeled neuron. B) Immunofluorescence 
images of cultures infected with lentivirus expressing GFP-P2A-mCherry, 
GFP-P2A-mCherry:FL-WT or GFP-P2A-mCherry:RD-WT at ~2MOI. 20x 
images showing mCherry single positive neurons. Stained with anti-RFP (Red) 
and anti-GFP (Green). C) Quantification of sorted neurons infected with the 
GFP-P2A-_ viruses indicated. 
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Initially, it was very surprising to see that the viruses expressing mCherry 
tagged tau showed a small percentage of cells that were only positive for mCherry, 
and not GFP, possibly indicating that tau was in fact spreading in this paradigm 
(Figure 3.2B). However, this first experiment was performed without the proper 
control, a GFP-P2A-mCherry virus without any tau. Upon repeating the experiment 
with the proper control, the mCherry only virus also showed some neurons that were 
singly positive for mCherry (Figure 3.2B). The challenge then became to rule out the 
presence of any viral transgene in these single positive cells, as it was possible that 
these mCherry single positive cells either had an incomplete incorporation of the 
virus, or the virus randomly mutated the transgenes, inactivating GFP. After 
discussing a number of ways to do this, we decided to FACS sort the cells to look at 
the percentage of single positive cells. Unfortunately, the sorting experiment 
demonstrated that this experimental paradigm was incredibly variable. Examining 
the percentage of cells of the three individual populations (GFP+, mCherry+, and 
GFP+/mCherry+) for each virus, it was clear that there was no consistent trend in 
the number of cells within each population in each infection (Figure 3.2C). While the 
experiment showed that there was in fact more mCherry:FL-WT-tau single positive 
cells compared to the mCherry only condition (16.13% vs 1.13%), it also showed 
that the percentage of GFP single positive cells was incredibly variable amongst all 
five transgenes tested (mCherry only, FL-WT, FL-P301L, RD-WT, RD-P301L; 
9.57%, 71.1%, 49.4%, 17.77%, 50.16% respectively), highlighting that the lentivirus 
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is highly unpredictable, and may be randomly inactivating or mutating the 
transgenes (Figure 3.2C). As a result, we concluded that this paradigm was too 
variable to continue forward with it as a method to study tau spreading.  
Tau spreads from donor to recipient neuron as efficiently as the control 
Despite the background of the donor cell lines not being a full tau knockout as 
highlighted in Chapter 2, I continued to generate neurons from these lines with the 
intention of co-culturing donor and recipient cells to observe spreading. Donor and 
recipient iPSCs were induced alongside each other for 30-36 days, until they formed 
immature NPCs. At this point, donor and recipient NPCs were plated together at a 
donor to recipient ratio of 2:1. Initial experiments had demonstrated that as neurons 
mature (50-60 days), their ability to respond to doxycycline diminished based on the 
epifluorescence of mCherry (data not shown). As such, two days after plating NPCs, 
doxycycline was added to the culture media at 1 µg/mL, and was maintained by 
replacing half of the media every two to three days. 
Previous work by Kim Olsen, Dominik Paquet, and Dylan Kwart in the lab 
demonstrated that neurons only begin to show the characteristics of mature neurons 
around DIV60-70, based on electrophysiological properties of the neurons (data not 
shown). As a result, all experiments were allowed to mature for at least 60 days, to 
ensure the formation of functional synapses. 
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After optimizing the cell culture conditions and doxycycline dosing, co-cultures 
were fixed and imaged using confocal microscopy to generate a three-dimensional 
image of cell bodies. I specifically focused on cell bodies because without super 
high-resolution imaging, I would not be able to differentiate donor tau within a 
recipient axon from two fasciculated donor and recipient axons or dendrites. 
Therefore, larger volume cell bodies were studied as the resolution of the confocal 
microscope would allow for the detection of mCherry puncta within the labeled 
membrane of the recipient cell. 
In co-cultures with mCherry tagged FL-WT tau, I was in fact able to detect 
rare instances where there were mCherry+ puncta residing within a memYFP 
recipient cell bodies (Figure 3.3A). This event seemed to occur at a rate of roughly 
10% of all counted recipient cells (Figure 3.3A and C). This was initially very 
encouraging evidence that tau spread between neurons. However, examination of 
the control cell line expressing the mCherry fluorophore alone showed that mCherry 
spread to recipient cells just as well as mCherry tagged tau (Figure 3.3A and C). In 
fact, it spread perhaps even better than tau (15% vs. 10%), and even resulted in 
some cells appearing to have space filling quantities of the mCherry fluorophore 
(Figure 3.3B). These results suggest that the spreading being observed in these co-
cultures is not specific to tau, and may in fact be a generalized process such as bulk 
endocytosis. While this is not a far-fetched conclusion, to prove this was a non-
specific process would have required the generation of several additional control 
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lines, including lines expressing tagged proteins of variable size, structure, 
phosphorylation state, charge, and subcellular localization. Another interpretation of 
these results is that the mCherry fluorophore is actually facilitating the transfer of 
tau, and the spreading observed is therefore unrelated to the potential disease 
mechanism. These interpretations, coupled with the fact that the inducible 
expression system only allowed for continuous expression of tau starting at the NPC 
stage of differentiation, led me to pursue a new method to model tau spreading in 
iPSC-derived neurons. 
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Figure 3.3. Tau and mCherry CTL spread into recipient neurons. A) Three 
representative images of memYFP WT recipient cells with mCherry+ staining within 
the recipient cell membrane (arrows) for FL-WT and mCherry CTL donor co-
cultures. Immunolabeled with anti-GFP (green), anti-mCherry (red) and nuclei (blue), 
63x orthogonal views in XZ and YZ planes. B) Representative image of mCherry 
CTL co-culture with memYFP WT recipient cell displaying space filling mCherry 
staining. C) Quantification of the rate of spreading in the mCherry CTL and FL-WT 
co-cultures. N=32 recipient cells counted for mCherry CTL, and n=78 recipient cells 




Recombinant tau aggregates are macropinocytosed in HEK293 cells 
Because the donor and recipient co-culture method for studying the spread of 
tau posed a number challenges that would be difficult to overcome, I turned to using 
recombinant tau aggregates to investigate the mechanism of tau uptake in human 
neurons. The ability to generate purified recombinant tau has been described and 
utilized for over a decade now (Barghorn et al., 2005). Fortunately, numerous 
protocols have been established to induce recombinant tau preparations to 
aggregate in vitro. The most common method requires a simple incubation with a 
poly-anionic molecule, such as heparin. Thankfully, my committee member and 
rotation advisor, Dr. David Eliezer, offered to share recombinant tau protein that I 
generated in his laboratory to use in the subsequent experiments. 
Table 3.1 Pharmacological inhibitors of cellular uptake mechanisms. 
Target	Pathway Compound









The goal of these experiments was to use pharmacological inhibitors of 
various cellular uptake mechanisms to prevent, or enhance recombinant tau uptake, 
in order to pinpoint how tau aggregates enter neurons. These pathways included 
clathrin mediated endocytosis, and macropinocytosis (Table 3.1). Furthermore, I 
also wanted to test whether tau aggregates would get degraded by the proteasomal 
degradation pathway after uptake, by treating cells with lactacystin (Table 3.1). 
Following the methods of a recently published protocol (Holmes et al., 2013), 
I used Western blotting to confirm the successful aggregation of FL-WT tau 
preparations by heparin incubation (Figure 3.4A). After blotting for total tau (K9JA) 
under reducing and non-reducing conditions, a streak of tau appears in the 
aggregate preparation, indicating the successful aggregation of tau into dimers, 
trimers, and larger oligomers and fibrils (Figure 3.4A). Furthermore, these 
aggregates return to monomeric form after exposure to reducing agent (BME), 
suggesting that these aggregates form disulfide bridges (Figure 3.4A) 
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Figure 3.4. Characterization of recombinant tau aggregates. A) Western blot for 
total tau (K9JA) of recombinant FL-WT tau. Recombinant protein was incubated in 
the presence or absence of heparin to generate aggregates (Aggs) and monomers 
(Mono) respectively. Preparations were incubated with heparin for either 24 or 
48hrs, under reducing and non-reducing conditions (+/- BME). 
Prior to testing these aggregates and their mechanism of uptake in neurons, I 
first wanted to confirm that these aggregates were in fact capable of seeding and 
inducing aggregation of soluble, monomeric tau in vitro. Recent studies have 
demonstrated that tau aggregates induce monomeric tau to misfold and aggregate, 
much like prion protein (PrP) in CJD and Scrapie (Sanders et al., 2014). Importantly, 
the injection of brain homogenates containing tau aggregates from affected 
transgenic mice are capable of transmitting its pathological conformation to 
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unaffected WT animals, confirming tau aggregates possess bona fide prion-like 
properties (Sanders et al., 2014). Recently, an in vitro human embryonic kidney 293 
(HEK293) cell culture tool was generated that acts as a biological sensor for tau 
aggregation potential (Holmes et al., 2014). These cells express a CFP:YFP FRET 
pair tagged to a P301S mutant tau RD in the cytosol. Upon introduction of tau seeds, 
the RDs aggregate and the CFP:YFP FRET pairs are brought into close proximity, 
allowing for the detection of a FRET signal. The RD aggregates are readily visible 
under a fluorescent microscope. 
I took advantage of the tau biosensor cells to test whether our aggregates 
were capable of seeding soluble tau. Importantly, I was only able to detect 
aggregation of CFP:YFP tagged RD when aggregates were pre-incubated with 
liposomes (Figure 3.5A), demonstrating that the aggregates required liposomes, or 
at least some sort of lipophilic interaction, to access the cytosol.  In addition, 
aggregates consisting of only a RD was much more efficient at inducing aggregation 
that the FL-WT aggregates, suggesting a possible seeding barrier between FL tau 
aggregates and the soluble RD sensor (Figure 3.5B). 
Having demonstrated that these aggregates can enter these biosensor cell 
lines, I performed a small scale pharmacological screen to assess the potential 
uptake mechanism using the inhibitors listed in Table 3.1. Interestingly, pretreatment 
of the biosensor cells with heparin or 5-N-ethyl-N-isopropyl-amiloride (EIPA), 
inhibitors of macropinocytosis, completely blocked intracellular aggregation of tau in 
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cells treated with the liposomal RD aggregate preparations (Figure 3.6C). In 
addition, cytochalasin-D and latrunculin, which partially inhibit micropinocytosis via 
inhibition of actin polymerization, reduced, but did not completely inhibit aggregate 
formation. These data support and confirm previously reported findings that 
macropinocytosis, and specifically heparan sulfate proteoglycans, HSPGs, mediate 
the entry of tau fibrils into HEK293 cells (Holmes et al., 2013). 
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Figure 3.5. Tau aggregates require liposomes and bulk endocytosis for 
seeding. A) HEK293 Tau-Biosensor cell line treated with recombinant tau 
preparations for 24 hrs at 50nM, with and without liposomal pre-treatment of tau 
preps. B) Enlarged image of tau FL and RD aggregates with liposomes 
demonstrating seeding. C) Pretreatment with inhibitors of cellular uptake and 
proteasomal degradation for 24 hrs prior to RD aggregate treatment with liposomes. 
All images shown are CFP and YFP epifluorescence, 20x. FRET signal not reported. 
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I next wanted to determine whether this approach could also be applied in 
iPSC-derived neurons. Specifically, I set out to test if exogenous aggregates would 
be taken up by neurons and, if so, whether they would induce a conformational 
change in endogenous tau. Such a system would allow me to test and confirm 
whether macropinocytosis also mediated uptake of tau aggregates in human cortical 
neurons. However, this required a method to detect aggregated cellular tau, and 
discriminate aggregated cellular tau from the recombinant tau used for seeding. For 
this purpose, I took advantage of an antibody that specifically recognizes misfolded 
or aggregated tau (MC1) (Jicha et al., 1997). Because the MC1 antibody recognizes 
two epitopes on the tau protein when they come into close proximity, one in the N-
terminus, and one more C-terminal in the third RD (Figure 3.6A), it should not cross-
react with recombinant tau aggregates as they are composed of only the RD. I 
confirmed this specificity by Western blot, demonstrating that the MC1 antibody only 
recognizes FL tau (Figure 3.6B). Unfortunately, the MC1 antibody only stained 
neuronal cultures incubated with FL aggregates, and not RD aggregates (Figure 
3.6C). Because the RD aggregates were more efficient than the FL aggregates at 
aggregating endogenous tau in 293 cells, it is probable that the signal in neurons 
incubated with FL aggregates is caused by recognition of the recombinant protein by 
the MC1 antibody. If these aggregates were capable of seeding endogenous tau 
produced by the neurons and inducing conformational change, then I would expect 
that cultures seeded with RD aggregates would have also been stained with the 
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MC1 antibody. Because this was not the case, I suspect that these aggregates are 
not capable of entering neurons to induce a conformational change in endogenous 
tau. Therefore, these neurons are not fit to study the mechanism of tau uptake and 
seeding using the aggregates I produced. 
Conclusions 
In this chapter I explored tau spreading, a potential AD disease mechanism. 
My initial goal was to establish a model that reproducibly exhibits tau spreading in 
human iPSC-derived cortical neurons. Once established, this model would then be 
used to determine the mechanism of tau spreading using pharmacological inhibitors 
of various cellular release and uptake mechanisms. 
Preliminary studies with human and mouse co-cultures demonstrated 
the need for appropriately labeled donor and recipient cell lines in order to track tau 
as it moves from neuron to neuron. Furthermore, these studies highlighted the need 
for inducible overexpression of tau in order to increase the probability of observing 
tau spreading, and temporally control the expression of tau so that I may reliably 
determine the mechanism of spreading. An alternative approach to studying tau 
spreading using lentiviral overexpression of labeled tau yielded results that 
demonstrated the highly unpredictable nature of lentiviral infection, as neurons 
infected with a virus expressing GFP followed by a P2A sequence and mCherry 
tagged tau not only showed GFP+/mCherry+ cells, but also a significant proportion 
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of GFP+ and RFP singly positive neurons. As such, I proceeded forward with the 
donor and recipient co-culture method I originally proposed. 
Once optimized, these co-cultures demonstrated a low baseline of tau 
spreading from donor to recipient neurons, about 10%. However, the fluorophore 
control cell line also spread at a roughly equal rate as tau, indicating that the 
spreading observed was not specific to tau, and therefore likely a generalizable 
mechanism of uptake of random extracellular contents. Furthermore, the inducible 
system I designed unfortunately did not allow for the temporal expression of the 
fluorescently labeled tau, therefore making the model system unsuitable for direct 
modulation of tau spreading and determination of the spreading mechanism via 
pharmacological inhibition. 
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Figure 3.6. Recombinant tau aggregates cannot induce conformational change 
in endogenous tau. A) Schematic of tau protein with MC1 antibody epitopes. B) 
Western blot of FL and RD recombinant monomers and aggregates. Blotted for total 
tau (K9JA) and MC1. C) Immunostaining of memYFP WT neurons, DIV70, treated 
for 96hrs with 50nM vehicle, monomer and aggregates of both FL and RD, for MC1 
(red) and GFP (green). Nuclei stained with Hoechst (Blue). 
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I therefore turned to using recombinant tau preparations in order to hopefully 
study the uptake of tau aggregates in vitro. Initially, I characterized tau uptake in a 
recently generated HEK293-biosensor cell line to measure the ability of tau 
aggregates to induce seeding and conformational change of soluble tau. Aggregates 
prepared with liposomes were able to induce aggregation of the tau RD expressed in 
these biosensor cells, indicating that they were readily accessing the cytosol and 
inducing conformational change of previously normal tau. Upon pharmacological 
inhibition of macropinocytosis, aggregates were incapable of seeding in these 
biosensor cell lines, confirming previous studies and supporting the hypothesis 
generated from the donor and recipient cell line data, that tau and other cellular 
products are being taken up by a non-specific bulk endocytic mechanism. 
I then attempted to translate these findings to human iPSC-derived neurons. 
Unfortunately, in my hands tau aggregates were not able to seed endogenously 
expressed tau, therefore limiting my ability to determine the mechanism of entry into 
neurons as I did not have a functional assay. This does not preclude the possibility 
that these aggregates are gaining access to the intracellular compartment. However, 
it is clear that these aggregates were incapable of causing templated misfolding of 
endogenous tau in this experimental paradigm, which could reflect that the 
aggregates simply are not getting into the neurons, or are getting degraded in 
subcellular compartments upon entry, such as in the endosomal/lysosomal system. 
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Chapter IV: PSEN1 FAD mutations impair g-secretase function 
Background and Rationale 
The amyloid cascade hypothesis has been a widely accepted theory that 
describes the molecular pathogenesis of AD (Hardy and Higgins, 1992). Central to 
this hypothesis is the idea that Ab, the major protein entity in amyloid plaques, is not 
only necessary for the development of AD, but also the initiator and key mediator of 
the downstream effects that follow Ab deposition. For the last 25 years, this 
hypothesis has been widely supported, but has yet to be completely confirmed. 
From a genetic viewpoint, it makes sense that Ab would be central to the 
disease, as mutations in APP as well as PSEN1 and PSEN2, which function in Ab 
production, are all causal of FAD. Furthermore, mutations in APP generally cluster 
around the sites of APP processing by either BACE or g-secretase, or promote 
aggregation of Ab peptides (Figure 4.1) (Grant et al., 2007; Lazo et al., 2005; Van 
Dam and De Deyn, 2006; Weggen and Beher, 2012). On the flip-side, a missense 
mutation in the Ab region of APP that protects against AD has now been described 
(Jonsson et al., 2012; Kero et al., 2013), supporting how critical Ab is to the 
development of AD. 
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Figure 4.1. FAD mutations in APP. Schematic of mutations in APP that cause FAD 
cluster around the BACE and g-secretase processing sites. Mutations within the Ab 
fragment themselves do not alter processing of Ab, but rather enhance aggregation 
(blue box). One mutation, A673T, is protective against AD (green box). (Figure 
reprinted with permission from (Van Dam and De Deyn, 2006)). 
Interestingly, more than two-thirds of all FAD mutations are found in PSEN1, 
228 in total, highlighting the importance of the production and processing of Ab. 
PSEN1 is a multipass transmembrane aspartyl-protease of 467-amino acids, 121 of 
which are mutated in FAD (alzforum.org). PSEN1 is the catalytic component of the 
multiprotein g-secretase complex. This multiprotein complex has numerous biological 
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functions in addition to the production of Ab, including the cleavage of Notch1 to 
release the Notch intracellular domain (NICD) (De Strooper et al., 1999; Hartmann et 
al., 1999), and the cleavage of N-Cadherin (Marambaud et al., 2003) (Haapasalo 
and Kovacs, 2011). Importantly, PSEN1/g-secretase performs its protease activity 
within the plasma membrane, designating it as an intramembrane cleaving protease 
(I-CLiP), and explaining its ability to process Ab, which resides within the membrane, 
from b-CTF (Weihofen and Martoglio, 2003). 
Initial insight into how PSEN1 and g-secretase function in AD came from the 
demonstration that the enzyme complex acts to increase the amount of Ab42 
relative to Ab40, or in other words increase the ratio of Ab 42:40, in the diseased 
state (Borchelt et al., 1996; Citron et al., 1996; 1997; Duff et al., 1996; Klafki et al., 
1996; Scheuner et al., 1996). These initial findings concluded that PSEN1 mutations 
in FAD lead to the preferential generation of Ab42, the longer and more aggregation 
prone Ab species. Unfortunately, many interpreted these data to mean that PSEN1 
mutations were gain-of-function due to elevated production of longer Ab species. 
However, these experiments were performed prior to a complete understanding of 
the mechanism of PSEN1/g-secretase cleavage of b-CTF, and therefore a true 
designation of gain-, or loss-of-function could not be given. Shortly after these initial 
experiments, researchers began to collect data that suggested the opposite, that 
PSEN1 mutations may result in a partial loss of function (Lewis et al., 2000; Song et 
al., 1999). One such study showed that FAD PSEN1 mutations reduce Notch 
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processing (Song et al., 1999), while another showed that a known loss of function 
mutation in PSEN1 that does not occur in humans, also increases the amount of 
Ab42 relative to Ab40 similar to FAD PSEN1 mutations (Lewis et al., 2000), 
suggesting that the rise in Ab42 is perhaps a consequence of decreased PSEN1 
function. 
In fact, as cellular models of FAD PSEN1 began to emerge, more evidence 
supported that these mutations may actually result in a partial loss of function 
because many mutations demonstrated that the increase in Ab 42:40 could also be 
caused by decreases in Ab40 (Bentahir et al., 2006; De Strooper, 2007). 
Furthermore, an FAD mutation was discovered in intron 8 at the splice acceptor site, 
along with a point mutation at the splice junction site between exons 8 and 10, 
resulting in the skipping of exon 9 (DE9) (Dumanchin et al., 2006; Perez-tur et al., 
1995). Importantly, exon 9 is the site of autocatalytic cleavage of PSEN1 into its NTF 
and CTF, which is required for catalytic activity of PSEN1, and therefore supports 
the idea that loss of PSEN1 function may be critical to the development of FAD 
(Bentahir et al., 2006; Dumanchin et al., 2006; Perez-tur et al., 1995; Thinakaran et 
al., 1996). Interestingly, PSEN1 knockout mice die shortly after birth due to severe 
skeletal and circulatory defects, which can be attributed to defects in Notch signaling 
(De Strooper et al., 1999; Hartmann et al., 1999; Shen et al., 1997). These results 
imply that PSEN1 FAD mutations are not complete loss of function, but rather partial 
loss of PSEN1 function. 
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Nevertheless, the debate over PSEN1 FAD mutation function has raged on. 
Fortunately, new insights reveal how PSEN1 processes APP (Takami et al., 2009). 
The study shows that PSEN1 initially performs an endopeptidase cleavage between 
either residue 50/49 or 49/48 of b-CTF, generating the AICD and Ab49 or Ab48. 
PSEN1 then goes on to create successive tri- or tetra-peptide carboxy-peptidase 
cleavages of Ab49 and Ab48 to ultimately create Ab40 or Ab38 respectively. 
Importantly, Ab38 is created from a tetra-peptide cleavage of Ab42, and Ab40 is 
generated from a tri-peptide cleavage of Ab43 (Figure 1.2). Both of these events 
occur during the fourth cleavage of Ab by PSEN1. With this in mind, it becomes 
apparent that the cause for the increase in the ratio of Ab 42:40 may be due to 
impaired function of PSEN1 during the fourth cleavage of b-CTF, resulting in 
increased Ab42, and perhaps even larger species of Ab like Ab43, as well as 
decreased Ab40 or Ab38. In fact, the increase in Ab42 initially observed in human 
serum and CSF (Scheuner et al., 1996), and transgenic mice (Citron et al., 1996; 
1997; Duff et al., 1996), may all be explained by a partial loss of function in the 
processing of APP by PSEN1. Recently, an elegant biochemical analysis examined 
the processing of Ab by several FAD PSEN1 mutations, showing consistent 
impairment of the fourth enzymatic cleavage of b-CTF by these FAD mutations 
(Chávez-Gutiérrez et al., 2012). While the study showed a consistent lowering of 
Ab38 and Ab40, the levels of longer Ab42 and Ab43 varied. Furthermore, these 
experiments were performed in the background of a PSEN1/PSEN2 double 
82 
knockout MEFs rescued with overexpressed WT or FAD mutant PSEN1, along with 
overexpression of b-CTF, highlighting the extreme artificial nature of the 
experimental system. 
With these studies in mind, I decided to investigate the function of PSEN1 in 
iPSC-derived human cortical neurons. This approach allows us to study the 
mechanism of Ab production in human neurons expressing physiologically relevant 
levels of g-secretase and its substrates. As discussed in Chapter 2, I utilized recent 
advances in CRISPR/Cas9 genome editing to accurately introduce several FADS 
causing PSEN1 mutations (M146V, L166P, M233L and A246E) into WT iPSCs. All 
of these mutations are reported to increase the ratio of Ab 42:40. In addition, 
members of our lab demonstrated that the M146V mutation increased the Ab 42:40 
ratio in the parental iPSCs line I would use for introducing the other FAD PSEN1 
mutations (Figure 4.2) (Paquet et al., 2016). However, I intended to elaborate on 
their findings, and specifically describe how each mutation alters the production of 
each Ab species (Ab38, Ab40, and Ab42). This information, along with the total 
amount of Ab produced, and the effects on other PSEN1 substrates such as Notch1 
and N-Cadherin, would be informative in determining how FAD mutations in PSEN1 
affect its function. 
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Figure 4.2. The M146V mutation causes a genotype dependent increase in 
the Ab 42:40 ratio. Isogenic PSEN1 M146V mutant iPSCs demonstrate a 
mutation-load dependent increase in the ratio of Ab 42:40 in iPSCs (DIV0), 
neural precursors (NPs, DIV34), and neurons (DIV72). Values represent mean 
(n=3 biological replicates) ± s.e.m. **P < 0.05 and ***P < 0.001, one-way ANOVA 
(Reprinted with permission from (Paquet et al., 2016)). 
PSEN1 mutations cause increases in Ab42 and decreases in Ab40 and Ab38 
Following generation of the isogenic iPSC mutant lines, I differentiated them 
into cortical neurons. Neurons from each mutation were grown alongside WT 
neurons in each experiment, in order to better quantify and compare the changes in 
Ab production from experiment to experiment. Further, cell lines were divided into 
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three biological replicates on each plate. Neurons were differentiated for roughly 
three weeks after NPC plating, at which point media was completely changed, and 
allowed to condition for seven days. In each experiment, neurons were analyzed 
around day 60 (DIV 58-68). Each replicate was then harvested, collecting both 
supernatant and cellular lysates. Each supernatant was analyzed by an 
electrochemiluminescent (ECL) assay for Ab38, Ab40, and Ab42, as well as sAPPa 
and sAPPb. The total sAPP measurements were used to normalize samples for 
comparing Ab levels across samples as well as experiments. The rationale for using 
total sAPP is that it is a measure of a soluble secreted protein. 
Each of the FAD PSEN1 mutations demonstrated significant increases in the 
Ab 42:40 ratio (Figure 4.3A), and the Ab 42:38 ratio (Figure 4.3B). Importantly, the 
edited WT (WT/WT*) showed no change in these ratios when compared to the WT 
control, demonstrating that the silent PAM blocking mutation and manipulations of 
gene editing had no effect on these measurements (Figures 4.3A and B). Strikingly, 
the L166P homozygous mutant demonstrated dramatic increase in the Ab 42:40 and 
Ab 42:38 ratios, increasing ~13- and ~47-fold compared to WT respectively. This 
homozygous mutation also significantly reduced the total amount of Ab produced by 
almost two thirds (of note, total Ab refers to simply the sum of Ab38, Ab40 and Ab42) 
(Figure 4.3C). Though less dramatic, the heterozygous L166P mutant also 
demonstrated a significant reduction in total secreted Ab (Figure 4.3C). In addition, 
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the M146V homozygote, M233L heterozygote, and A246E homozygote also 
demonstrated significant reductions in total Ab (Figure 4.3C). 
When the individual components of these measurements are examined, an 
interesting pattern emerges. All mutants, except the A246E heterozygote and A246E 
hemizygote, demonstrated significant reductions in the amount of secreted Ab38 
(Figure 4.3D). The A246E mutation also produced less Ab38 than WT, but this 
difference was not statistically significant. In addition, Ab40 levels were also 
significantly reduced in all mutants, except for the A246E heterozygote (Figure 
4.3E). Ab 42 levels, on the other hand, were significantly increased in all mutant 
neurons (Figure 4.3F). These data support the hypothesis that mutations in PSEN1 
impair the final carboxypeptidase cleavage, causing reduced production of Ab40 and 
Ab38, and elevated levels of Ab42. Interestingly, not all mutations behaved 
identically, with some mutations demonstrating more severe changes in Ab 
production than others. 
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Figure 4.3. PSEN1 mutants increase the Ab 42:40 and 42:38 ratio by lowering 
Ab40 and Ab38, and increasing Ab42. A) Secreted Ab 42:40 ratio. Ab 42 and Ab40 
measurements were normalized to secreted total sAPP. B) Secreted Ab 42:38 ratio. 
Ab42 and Ab38 measurements were normalized to secreted total sAPP. C) Total 
secreted Ab as determined by the sum of Ab42, Ab40 and Ab38 when normalized to 
total secreted sAPP. D) Secreted Ab38. E) Secreted Ab40. Secreted Ab42. Bars 
represent measurements from at least three individual experiments (inductions). 
Error bars represent S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, one-
way ANOVA with Dunnett’s multiple comparisons post-test. 
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With this in mind, I examined whether any of these measurements correlated 
with, or could predict, disease onset. For this analysis, I plotted the Ab 42:40 ratio, 
Ab 42:38 ratio, total Ab, Ab38, Ab40, and Ab42 values for each heterozygous mutant 
cell line against the mean age of onset for each mutation as determined from clinical 
data, as the heterozygotes represent the actual patient genotype (Moehlmann et al., 
2002; Ryman et al., 2014). Remarkably, the Ab 42:40 ratio, and Ab40 levels showed 
a significant linear correlation with the age of onset, with correlation coefficients (R2) 
of 0.9996 and 1 respectively (Figure 4.4A and E). As expected, the Ab 42:40 ratio 
showed a negative correlation with disease onset, with higher ratios corresponding 
to lower age of onset. Ab40, on the other hand, exhibits a positive correlation, with 
lower Ab40 values corresponding to a lower age of onset. In addition, while the Ab 
42:38 ratio, total Ab, and Ab38 did not show linear correlations, these values did 
demonstrate monotonic relationships. (Figure 4.4B, C, and D). Interestingly, the 
Ab42 levels were relatively similar between the mutants, demonstrating the 
importance of the WT allele in processing Ab42 to Ab38 (Figure 4.4F).  
Interestingly, when the values for the homozygous mutants are similarly 
plotted against the mean age of onset, a different correlation emerges. Namely, the 
only value with a linear correlation to age of onset in homozygotes is Ab42 levels, 
with an R2 value of 0.9949 (Figure 4.5F). Importantly, all other values plotted 
demonstrate monotonic relationships with age of onset (Figure 4.5A, B, C, D, and 
E). 
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Figure 4.4. Ab 42:40 ratio and Ab40 correlate with disease onset in 
heterozygotes. Mean age of onset plotted against heterozygous mutant 
measurements for A) Ab 42:40, B) Ab 42:38, C) Ab Total, D) Ab38, E) Ab40 and F) 
Ab42. Error bars represent S.E.M, with a best fit linear regression line. Pearson 
correlation coefficient (R2) and P value reported. 
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Figure 4.5. Ab42 correlates with disease onset in homozygotes. Mean age of 
onset plotted against homozygous mutant measurements for A) Ab 42:40, B) Ab 
42:38, C) Ab Total, D) Ab38, E) Ab40 and F) Ab42. Error bars represent S.E.M, with 
a best fit linear regression line. Pearson correlation coefficient (R2) and P value 
reported. 
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PSEN1 mutations impair g-secretase-dependent functions 
g-secretase cleaves over 90 different substrates, some of which carry out 
critical cellular functions such as Notch1 signaling (Haapasalo and Kovacs, 2011). 
To further examine the partial loss of function phenotype observed in Ab production, 
I also measured the processing of APP CTFs, Notch1 CTF and N-Cadherin CTF by 
Western blot. If these mutations impair g-secretase processing, then these CTFs 
would be expected to accumulate. Unfortunately, Notch1 CTF levels were not 
detectable in these samples, and thus could not be assessed. Interestingly, 
heterozygous mutants showed slight increases in the CTFs assessed (Figure 4.6B). 
However, the homozygous mutants M146V, L166P and A246E showed large 
increases in APP a- and b-CTFs compared to WT (Figure 4.6B). In contrast, only 
the L166P homozygous mutant demonstrated an increase in the N-Cadherin CTF 
(Figure 4.6B). Importantly, none of the mutations had an effect on the ability to form 
functional g-secretase products, as no drastic changes in the abundance of the key 
components of g-secretase, PSEN1 N-terminal fragment (NTF), PSEN2, NCT, and 




Figure 4.6. Mutant neurons do not demonstrate significant changes in g-
secretase expression, and impaired cleavage of b-CTF and N-Cadherin. A) 
Western Blot of WT and mutant neurons showed similar expression profiles of g-
secretase components, PSEN1, PSEN2, NCT, and PEN2. B) Western Blot of APP 
(FL and CTFs) and N-Cadherin show impaired g-secretase cleavage of APP a- and 




 In this chapter I explored the specific contributions of several FAD PSEN1 
mutations to Ab production, and g-secretase function in general. I found that these 
mutations, M146V, L166P, M233L and A246E, all increase the ratios of Ab 42:40 
and Ab 42:38, which are attributed to by both decreases in Ab40 and Ab38, and 
increases in Ab42. From this I can conclude that the last carboxy-peptidase 
cleavage of APP is impaired, demonstrating that these FAD mutants cause a partial 
loss of PSEN1 function. Furthermore, Ab 42:40 and Ab40 show significant 
correlation to the mean age of onset for these mutations in heterozygotes, 
suggesting that these measurements may have clinical predictive value. In addition, 
homozygotes show a correlation in the levels of Ab42 with the mean age of onset, 
indicating not only that Ab42 levels are important, but also that the WT allele in 
heterozygotes plays an important role in limiting the accumulation of Ab42. Lastly, I 
show that only homozygous mutations cause an elevation in APP CTFs, and the 
L166P homozygous mutation causes an increase in the N-Cadherin CTF. This 
supports the conclusion that these mutations are partial loss of function, but also 
demonstrates that in the presence of a WT allele, g-secretase exhibits some normal 
function, as heterozygous mutants showed reduced effects on APP or N-Cadherin 
CTF processing compared to the homozygotes. Taken together, these isogenic cell 
lines demonstrate the ability to replicate APP processing phenotypes in a 
physiologically relevant manner. 
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Chapter V: Discussion and Future Directions 
  
 Despite decades of advances, there is still much to learn about the 
pathogenesis of AD. While it is clear that all AD patients exhibit amyloid plaques and 
NFTs, we still don’t fully understand how, or even if, these protein deposits cause 
neurodegeneration and subsequent cognitive decline. Therefore, it is critical to 
thoroughly investigate the molecular and cellular events that lead to the formation of 
amyloid plaques, NFTs, and the downstream consequences of all of their resulting 
byproducts. Understanding all of these mechanisms will dictate which therapeutic 
targets could be most effective. Perhaps the lack of a clear understanding of 
pathogenic mechanisms in AD can be attributed to the inability of in vivo or in vitro 
models to adequately recapitulate AD phenotypes. Even the models that come close 
to replicating most histopathological and behavioral phenotypes still require non-
physiologic overexpression of several transgenes. Here, I attempt to address the 
lack of appropriate AD models by generating two models in human iPSCs with the 
intention of improving our understanding of two specific disease mechanisms. The 
first model attempts to recapitulate tau spreading in order to examine the 
mechanism by which tau propagates. Unfortunately, I show that this model was not 
only cumbersome and non-physiologic, but also that the control mCherry protein 
spreads just as efficiently as tau. The second model utilized CRISPR/Cas9 genome 
editing to introduce several FAD PSEN1 point mutations at endogenous loci into WT 
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iPSCs. This method preserves endogenous levels of expression of g-secretase and 
APP, allowing for the characterization of Ab production in a physiologically relevant 
system. I show that PSEN1 mutations cause a partial loss of function in g-secretase 
processing of APP, which not only replicate AD phenotypes, but also correlate with 
disease onset. By demonstrating these disease phenotypes with endogenous 
expression levels, we believe that this model system is an improvement upon the 
existing cell culture models, and should be used in future studies to further our 
understanding of AD mechanisms, and screen for potential therapeutics. 
 
Spreading may not be a property inherent to tau 
 In Chapter 3, I established a co-culture system comprised of tau donor and 
recipient cell lines with the hopes of confirming that tau spreads from neuron to 
neuron. I reasoned that this system, if successful, would be a significant advance for 
the field, as it would allow for the direct observation and manipulation of tau 
spreading in human neurons. The current view in the field is that an uncharacterized 
pathologic tau species spreads trans-synaptically along anatomically connected 
paths in the brain, facilitating the misfolding and aggregation of previously healthy 
tau protein in a prion-like manner, and thus potentiating the disease. However, the 
mechanism by which this species is released and taken up is still debated. 
Therefore, understanding this mechanism would identify potential therapeutic 
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targets. Importantly, understanding this process in human neurons in vitro may 
increase the probability of translating these findings to human patients.  
Indeed, I observed that mCherry tagged tau does in fact spread from donor to 
recipient neurons in this transgenic inducible system (Figure 3.3A and C). However, 
I was disappointed to find that the control, mCherry alone, also spreads just as 
efficiently as tau (Figure 3.3B and C). This complicates the interpretation of the 
results, as there are two possible interpretations of these data: 1) tau and mCherry 
are randomly internalized by recipient neurons by a non-specific process such as 
bulk endocytosis or 2) the mCherry tag is actually facilitating tau spreading. Future 
studies required to distinguish these possibilities are outlined in the section below, 
and would have required a substantial time commitment, several more years, that 
the lab and I unfortunately could not afford. As such, my effort to study the 
mechanism of tau release and uptake in human neurons was stalled. 
Because of these difficulties, I turned to studying one particular aspect of tau 
spreading in isolation, namely, cellular uptake of tau oligomers. Recently, a cell 
culture tool was established that could sense the aggregation potential of tau 
aggregates (Holmes et al., 2014). These HEK293 cells express the tau RD tagged to 
a CFY or YFP FRET pair. Upon introduction of exogenous recombinant aggregates, 
lysates from transgenic mouse brains harboring NFTs, or even human AD brain 
lysates, the RD FRET pairs aggregate which is visible with fluorescence microscopy. 
Using recombinant tau preparations from Dr. David Eliezer’s laboratory, I 
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demonstrated that exogenous tau aggregates, but not monomers, were capable of 
seeding aggregation in these biosensor cells (Figure 3.5A and B). 
Importantly, these aggregates required the assistance of liposomes in order 
to seed aggregation (Figure 3.5A). This could have important biological implications, 
as it suggests that for tau to enter cells and access the cytosolic compartment where 
endogenous tau is expressed, a lipophilic carrier, such as an exosome, may be 
necessary. In fact, exosomal delivery of tau seeds has gained significant support as 
a possible mechanism for tau spreading, as several groups have reported detecting 
tau within exosomes, and have demonstrated their potential role in tau spreading in 
vivo (Asai et al., 2015; Saman et al., 2012; 2014; Santa-Maria et al., 2012). Our data 
support, but do not directly test, a role for exosomal transport of tau from donor to 
recipient, and should be investigated in an appropriate iPSC model. 
I next attempted to elucidate the mechanism by which liposomal tau 
aggregates gain entry into the biosensor cell line. Using pharmacological 
manipulation of cellular uptake mechanisms, I observed that inhibition of 
macropinocytosis, a form of non-specific endocytosis, reduced or completely 
inhibited aggregation in the biosensor cell line. These inhibitors included heparin, 
EIPA, latrunculin, and cytochalasin-D, which suggests that extracellular HSPGs are 
involved in mediating recognition of liposomal tau, and actin polymerization 
precipitates its physical engulfment. These data support previous studies, but 
elaborate upon them by demonstrating that these mechanisms are in fact required 
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for seeding and aggregation of tau expressed in the biosensor cell line (Holmes et 
al., 2013; Karch et al., 2012; Wu et al., 2013). Once inside the macropinosome, the 
liposomal tau somehow escapes the macropinosome to facilitate seeding and 
aggregation of the biosensor, however the escape mechanism remains 
uninvestigated. 
Nevertheless, with this mechanism in HEK293 cells confirmed, I then 
attempted to translate it to human neurons. Liposomal tau was added to WT 
neurons, anticipating that the endogenous tau would aggregate in a similar manner 
to the biosensor tau. To measure this, I used an antibody that recognizes only 
misfolded and aggregated tau, MC1. Initially I observed robust MC1 staining in 
neurons treated with FL-WT aggregates (Figure 3.7C). However, this experiment 
did not exclude the possibility that the MC1 antibody was recognizing and staining 
the exogenous aggregates, rather than endogenous seeded tau. To overcome this, I 
repeated the experiment with tau RD aggregates, which lack one of the epitopes 
required for recognition by MC1. If endogenous tau was in fact being seeded by 
these aggregates, then the MC1 antibody would still recognize and stain these 
cultures. Unfortunately, treatment with RD aggregates showed no staining with MC1, 
indicating that the liposomal tau preparations were not capable of replicating the 
results from the biosensor cell line in human neurons (Figure 3.7C). 
While these data were collectively disappointing, there are still some 
important takeaways. First, tau was able to transfer from one cell to another in a co-
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culture system. Though we could not conclude that the spreading observed was 
either a non-specific macropinocytosis, or the mCherry tag facilitating the transfer, 
both of these potential conclusions warrant follow up studies. Currently the field 
firmly believes that tau spread trans-synaptically by some mechanism that is 
inherent to tau. However, our data suggest the opposite, that tau spreads either via 
tau-independent bulk endocytosis, or with help from other protein interactions. These 
are important hypotheses that need to be fully investigated prior to developing 
therapies that target tau spreading, as blocking a generalized spreading mechanism 
may have unintended consequences if other proteins use similar pathways, or even 
use tau, to move from cell to cell under normal conditions. 
Second, I demonstrate that recombinant liposomal tau aggregates are 
capable of seeding aggregation in a HEK293 biosensor cell line via 
macropinocytosis. This observation fits with the hypothesis that tau spreads via non-
specific bulk endocytosis. Although I could not confirm the findings in neurons, I 
cannot exclude that this process is unique only to the biosensor cell line. I relied on 
the recombinant aggregates being able to seed endogenously expressed tau, which 
assumes that 1) the neurons take up tau, 2) the engulfed tau is not degraded and 
can access the cytosol, and 3) the recombinant tau can seed endogenous tau. 
These are several steps that can be addressed more systematically in future 
experiments, which should ensure that the aggregates are in fact taken up in 
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neurons, are not degraded upon engulfment, and subsequently access the cytosol to 
promote seeding. 
 
Future directions for tau spreading 
Future studies should begin with a focus on elucidating the mechanism by 
which recombinant tau preparations enter a neuron, and if they can induce 
aggregation. This property is at the center of the tau spreading hypothesis, that 
oligomeric tau can cause conformational changes in tau in a previously healthy 
neuron. I have already established that tau can enter and seed tau in the biosensor 
cell line. The next experiment should attempt to replicate the seeding phenotype in 
biosensor cells, however with the aggregates labeled with a fluorophore, such as an 
Alexa Fluor (Panchuk-Voloshina et al., 1999). If these labeled aggregates are still 
capable of seeding the biosensor cell line, then these could be used to track cellular 
uptake in neurons and ensure that the aggregates are being endocytosed. 
Subsequent experiments can then track where these aggregates are shuttled, either 
into the lysosomal system, or if they escape into the cytosol.  
Interestingly, in an experiment performed in collaboration with Dylan Kwart, 
whose work in the lab is focused on endosomal trafficking of APP and b-CTF, we 
observed that liposome-free tau aggregates accumulated in the endosomes of HeLa 
cells that were transiently transfected with a constitutively active Rab5A, which halts 
endocytic sorting at the early endosome stage, leading to enlarged endosomes that 
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do not mature into lysosomes (data not shown) (Calafate et al., 2016). While this 
experiment was not performed with the intent of studying tau uptake, it is highly 
suggestive that tau aggregates are potentially taken up and sorted through the 
endosomal-lysosomal system for degradation. An interesting follow-up experiment 
would be to transfect constitutively active Rab5 into the biosensor cell line, and then 
attempt to seed these cell with liposome-free aggregates. If liposome-free 
aggregates are capable of seeding the biosensor cell line, this would provide 
evidence that endosome-lysosome disruption (one of the earliest known pre-clinical 
changes seen in AD patient brains (Cataldo et al., 2000; 2001)) is responsible for 
allowing tau aggregates to escape and access the cytosol and may in fact be 
necessary for tau spreading and seeding in neurons. 
Once the recombinant aggregate experiments are completed and 
demonstrate an ability to enter neurons, and a mechanism by which they enter 
neurons is confirmed, the results should be subsequently confirmed in a co-culture 
system similar to what I originally proposed. This is important because recombinant 
aggregates, while useful, do not represent what occurs in an AD patient. In patients, 
spreading tau is produced by cells and post-translationally modified accordingly, 
whereas recombinant tau has no such alterations. Therefore, a donor and recipient 
co-culture method would more closely resemble what occurs in vivo. 
In order to rule out the potential effect that a protein tag could have on tau 
spreading, several more iPSC lines will need to be generated. First, I would attempt 
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tagging tau with smaller polypeptide tags such as FLAG or His. I would also attempt 
tagging proteins that have similar properties to tau, but show no evidence of 
spreading so far, such as microtubule associated protein 2 (MAP2) and MAP4. If all 
of these cell lines, including the tag-only controls, spread in a similar manner, then 
this would be highly suggestive of a tau-independent mechanism of protein 
spreading. Alternatively, and more ideally, future studies should avoid tagging tau 
altogether. To achieve this, the recipient iPSC cell line must be a true knockout of 
tau that does not exhibit any background immunofluorescence staining. This would 
allow for the faithful detection of donor tau within the knockout recipient without the 
use of fluorescent or short polypeptide tags. If tau is still observed to spread, 
pharmacological modulation of cellular release and uptake mechanisms could be 
used to elucidate a spreading mechanism, focusing on mechanisms elucidated in 
the recombinant tau experiments. In theory, this experiment could also be carried 
out in the absence of overexpression, allowing for the observation and manipulation 
of tau spreading at endogenous levels of expression. 
  
Is tau spreading a reasonable target for AD therapies? 
 If these experiments are capable of defining a mechanism by which tau can 
spread from one cell to another, it doesn’t necessarily mean that this pathway is a 
therapeutic candidate. As I have so far demonstrated, tau spreading may not be 
inherent to tau itself, and instead could be a more generalizable mechanism that 
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many proteins and cells utilize for critical biological functions. Targeting the pathway, 
therefore, may have unintended consequences in the clinic. However, since tau 
pathology closely correlates with disease severity, targeting tau is still a reasonable 
approach. In fact, several clinical trials have been initiated that either aim to break up 
and solubilize existing tau aggregates (Crowe et al., 2013; Wischik et al., 1996), or 
immunize patients against aggregated tau (Kontsekova et al., 2014). While we 
eagerly anticipate the results of these trials, it is still too early, and frankly unsafe, to 
presume that tau spreading is also a viable therapeutic target, as there is still much 
to understand. 
PSEN1 FAD mutants alter the processing of APP by g-secretase 
 In chapter 4 I explored whether PSEN1 FAD mutations result in gain- or loss-
of-function of g-secretase. Critical to making this determination is understanding 
what constitutes the normal function of g-secretase. It was initially assumed that g-
secretase preferentially made Ab40, the smaller Ab peptide that does not aggregate 
as readily as Ab42, and was therefore presumed to be less toxic. When it was 
discovered that PSEN1 mutations preferentially increased the amount of Ab42 
relative to Ab40, this was attributed to a toxic gain-of-function. Unfortunately, these 
experiments and conclusions were performed prior to a detailed understanding of 
how exactly PSEN1 cleaves b-CTF to produce Ab. Shortly after these seminal 
studies, researchers began to question whether these PSEN1 mutations were due to 
a gain of function to overproduce Ab42. Unfortunately, this has led to a sometimes-
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heated debate over PSEN1 FAD mutation function, and perhaps unfairly placed the 
blame for perceived misdirection on the investigators in these early studies. 
 Fortunately, a detailed explanation of how PSEN1 cleaves Ab has been 
provided (Takami et al., 2009), which demonstrated that the b-CTF undergoes 
successive tri- and tetra-peptide cleavages which produce Ab of varying lengths 
(Figure 1.2). This work demonstrated that a rise in Ab42 could actually be caused 
by a reduction in PSEN1 activity, specifically during the last carboxy-peptidase 
cleavage of b-CTF.  
With this in mind, I set out to determine whether PSEN1 FAD mutations could 
alter Ab production in iPSC-derived isogenic neurons. This system would provide a 
significant advance in the field, as most model systems that have been used to date 
have relied on massive overexpression of PSEN1, APP, and/or b-CTF, yielding 
results that have been variable from model to model, and could be difficult to 
translate to human patients. Only a handful of studies have used iPSC-derived 
neurons to study FAD PSEN1 mutations, however these either used non-isogenic 
controls (Liu et al., 2014; Nieweg et al., 2015; Sproul et al., 2014; Yagi et al., 2011), 
or overexpression of PSEN1 transgenes (Honda et al., 2016; Koch et al., 2012). 
Only one study has reported results from isogenic PSEN1 FAD iPSC lines, however 
only one mutation, DE9, was studied (Woodruff et al., 2013). The results presented 
here investigate four different isogenic iPSC lines, demonstrating the utility and 
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power of the recently establish CRISPR/Cas9 genome editing protocols in 
generating isogenic iPSCs for studying disease phenotypes. 
Analysis of the quantities of Ab peptides Ab42, Ab40 and Ab38 produced in 
isogenic mutant iPSC-derived neurons demonstrate a partial loss of function 
phenotype in g-secretase. In all mutant cell lines, Ab42 was increased (Figure 4.3F), 
while Ab38 and Ab40 were significantly decreased in all cell lines except for in the 
A246E heterozygote (Ab38 and Ab40), and the A246E homozygote (Ab38) (Figure 
4.3D and E). The L166P mutant cell lines demonstrated the most severe alterations 
in Ab production, particularly in a drastic reduction in Ab40 and Ab38 (Figure 4.3D 
and E). As a result of these alterations in Ab production, the Ab 42:40 and Ab 42:38 
ratios were accordingly increased in all mutants (Figure 4.3A and B). These data 
clearly demonstrate that g-secretase is impaired in PSEN1 FAD mutants, specifically 
during the last carboxy-peptidase cleavage of b-CTF, supporting the hypothesis that 
PSEN1 mutations are in fact partial loss of function. 
Because each mutation behaved differently with respect to altered Ab 
production, I reasoned that these measurements might correlate with disease 
severity in FAD patients of a given mutation. To explore this, I attempted to correlate 
the age of onset for a given mutation to the various Ab measurements in 
heterozygous mutants, as these cell lines represent the FAD genotype. 
Fascinatingly, there were significant correlations between the Ab 42:40 ratio and the 
Ab40 levels (Figure 4.4A and D). While it is relatively easy to generate a line 
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between three points, it was still remarkable that there was a significant correlation 
between these values. In addition, because there was a significant correlation 
between age of onset and Ab40, not Ab42, we can infer that the significance in the 
Ab 42:40 ratio is due to Ab40. While it has been shown that lower Ab42 in 
cerebrospinal fluid (CSF) is somewhat predictive of AD due to Ab42 incorporation 
into plaques, these data here could have implications in clinical practice and 
management of FAD and AD patients, as Ab40 measurements may be a more 
valuable diagnostic tool. Extrapolating further, these data may provide a hint that 
Ab40 may in fact have protective qualities, and that loss of Ab40 may precipitate 
Ab42 deposition. 
Further support for PSEN1 partial loss of function in FAD was observed when 
I examined other products of g-secretase cleavage. APP CTFs accumulated in the 
M146V and L166P homozygotes. Furthermore, the L166P homozygote also 
demonstrated an accumulation of the N-Cadherin CTF. These data suggest that 
these mutations impair g-secretase’s ability to cleave not only APP, but also other 
substrates. Interestingly, the presence of a single WT allele in heterozygotes is 
capable of maintaining the level of APP and N-Cadherin CTFs at or near WT levels. 
Because AD and FAD take decades to present with cognitive impairment, it is 
reasonable to assume that these CTFs may accumulate over time in AD and FAD 
brains, possibly contributing to cognitive impairment along with Ab.  
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In sum, these experiments demonstrate that PSEN1 mutations result in partial 
loss of g-secretase functions, as APP processing is significantly altered in a manner 
that points to an impaired carboxy-peptidase cleavage. Importantly, these data 
demonstrate the utility of the iPSC model system, as all of these experiments were 
carried out at endogenous levels of expression, therefore closely mimicking what 
occurs in human FAD patients. In addition, these studies highlight the importance of 
comparing iPSC mutant cell lines to isogenic controls, as all mutant iPSC lines had 
an identical genetic background, ruling out potential confounding genetic differences. 
We also demonstrate that recent advances in CRISPR/Cas9 techniques increase 
the feasibility of generating a large number of isogenic cell lines in a short amount of 
time, as this project was initiated only one year ago. 
 
Is Ab the source of disease in AD? 
 While our results presented here establish a functional role for PSEN1 in AD 
and FAD, we provide no evidence that Ab peptides are in fact the source of disease 
in AD. Future studies should, therefore, attempt to understand if, and if so, how, Ab 
ultimately leads to synapse loss and neurodegeneration, as this is the ultimate 
phenotype that leads to the manifestations of the disease in patients. Many studies 
have demonstrated that fibrillar Ab species are in fact synaptotoxic (Koffie et al., 
2009; Mucke et al., 2000; Nieweg et al., 2015; Walsh et al., 2002), which may in fact 
be a true mechanism by which Ab precipitates AD. However, this does not 
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necessarily fit with the observations that Ab plaque burden does not correlate with 
disease severity (Braak and Braak, 1991), that many aged humans have abundant 
plaques without any evidence of disease, or that all clinical trials aimed at directly 
reducing amyloid burden have so far failed (Selkoe and Hardy, 2016).  
 Interestingly, other byproducts of APP processing, such as the AICD, a- and 
b-CTFs, and longer intermediate forms of Ab such as Ab46, Ab45 and Ab43, remain 
understudied. Recently, work by Dylan Kwart in our lab identified alterations in the 
endosomal sorting pathway of neurons with isogenic FAD mutations. Namely, he 
noticed that homozygous FAD mutations result in increased levels of APP CTFs, 
which I confirmed in my homozygous mutants as well. Importantly, he observed 
these changes in PSEN1 mutants, and APP mutants, potentially identifying APP 
CTFs and endosomal-lysosomal sorting, not Ab, as a potential common perturbation 
underlying AD pathogenesis. Future studies are therefore aimed at identifying 
whether this is a common occurrence in all FAD genes (PSEN1, PSEN2, and APP), 
and whether these CTFs and impaired endosomal trafficking are responsible for 
neurodegeneration in FAD. 
Our data, together with the last several decades of studies, unequivocally 
demonstrates that alterations in APP processing leads to AD. Exactly how, and 
which byproduct of APP processing leads to AD remains elusive. However, I remain 
hopeful that cellular systems like the one presented here will be a useful tool in 
identifying targets for future therapies, and even screening for compounds that alter 
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disease related phenotypes. Whether that phenotype is increased Ab42, decreased 
Ab40, accumulation of APP CTFs, or tau spreading, I cannot definitely say. 
However, I am confident that the answers will soon become apparent.  
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Chapter VI: Materials and Methods 
 
iPSC lines.  iPSCs were reprogrammed from human skin fibroblasts (Coriell 
Institute, Catalog ID: AG07889) of an 18-year old male individual using the 
Cytotune-iPS Sendai Reprogramming Kit (Life Technologies) according to the 
manufacturer’s instructions (Paquet et al., 2016). Fibroblasts were confirmed to be 
wildtype for all studied loci by genotyping.  Multiple clones were selected based on 
characteristic morphology. Clone 7889SA possessed a normal karyotype (Cell Line 
Genetics) and was characterized for typical iPSC properties.  
Expression of pluripotent genes was analyzed by NanoString nCounter gene 
expression system using a pre-designed codeset (Kahler et al., 2013).  Data was 
normalized to the geometric mean of three housekeeping genes (ACTB, POLR2A, 
ALAS1) using the nSolver Analysis Software v1.0 (NanoString).  100 ng of total RNA 
from line 7889SA was compared to RNA extracted from the human ESC lines 
HUES9 (Cowan et al., 2004).  Gene expression for 7 pluripotency markers and the 4 
Yamanaka factors introduced as Sendai transgenes (s-t) was compared. Note that 
the s-tSox2 probe detects some expression of endogenous Sox2, leading to larger 
values for both lines.   
Expression of pluripotency markers Oct4, Tra160, SSEA4 and Nanog was 
confirmed by immunofluorescence. In vivo pluripotency was confirmed by teratoma 
analysis.   Undifferentiated iPSCs were embedded into Matrigel and subcutaneously 
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injected into the dorsal flank of immune-compromised mice (Jackson Laboratory). 
Paraffin sections of the teratomas were subjected to hematoxylin and eosin (H&E) 
staining and structures characteristic for the three germ layers (ectoderm, mesoderm 
and endoderm) were identified by microscopy.  
 
iPS Cell culture.  iPSCs were maintained on irradiated MEFs (Globalstem) plated 
on cell culture plates coated with 0.1% gelatin and grown in HUESM (Knock-out 
Dulbecco’s modified Eagle’s Medium (KO-DMEM), 20% knock-out serum, 0.1 mM 
non-essential amino acids, 2 mM Glutamax, 100 U/mL-0.1 mg/mL penicillin-
streptomycin (all Life Technologies), 0.1 mM 2-Mercaptoethanol (Sigma-Aldrich), 10 
ng/mL FGF2 (Stemgent), at 37 ºC with 5% CO2.  Prior to transfection, iPSCs were 
transferred to Geltrex-coated (Life Technologies) cell culture plates and grown in 
MEF-conditioned HUESM containing 10 µM ROCK inhibitor (Stemgent). 
 
TALEN gene editing. iPSCs were transfected with TALEN pairs targeting the H11 
locus (a gift from Michele Carlos, Addgene plasmid #51554 and 51555 (Zhu et al., 
2013)) and AAVS1 locus (a gift from Danwei Huangfu, Addgene plasmid #59025 
and 59026 (González et al., 2014)), by electroporation in order to generate recipient 
and donor cell lines respectively. Along with the TALEN pairs, repair templates were 
also electroporated with homology arms to H11 (a gift from Michele Carlos, Addgene 
plasmid #51546 (Zhu et al., 2013)) and AAVS1 (a gift from Rudolph Jaenisch, 
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Addgene #60843 and 22077 (Hockemeyer et al., 2009)). 2 million cells were 
resuspended in 100 µL cold BTXpress electroporation buffer (Harvard Apparatus) 
with 4 µg of each TALEN, and a total of 32 µg of donor repair template(s). Cells 
were electroporated at 70 mV for 20 ms in a 1 mm cuvette (Harvard Apparatus). 
After electroporation, cells were transferred to Geltrex-coated cell culture plates and 
grown in MEF-conditioned HUSEM containing ROCK inhibitor for 2 days. 100,000 
cells were then plated on 10 cm plates lined with MEFs. Cells were allowed to grow 
for 2 days before selection with either 250 µg/mL neomycin (G418, Life 
Technologies), or 250 µg/mL neomycin and 0.5 µg/mL Puromycin (Life 
Technologies). After selection for 7 days, colonies were allowed to grow until large 
enough to be manually picked into individual wells of a flat-bottom 96-well plate lined 
with MEFs in 100 µL of HUSEM with ROCK inhibitor. Incorporation of the mutant 
transgenes was analyzed by PCR (Table 6.1). 
 





Southern blot. Southern blot was performed as previously described (Southern, 
2006). Probe was generated by PCR amplification of the memYFP transgene. 
 
Lentiviral production. Lentiviral constructs and the associated packaging plasmids 
psPAX2 and pMD2G were transfected into 293FT cells using calcium phosphate. 
After 16-hours the media was switched to serum free viral production media: 
Ultraculture (Lonza), with 1% (v/v) penicillin-streptomycin/L-glutamine (Gibco), 1% 
(v/v) 100 mM sodium pyruvate (Lonza), 1% (v/v) 7.5% sodium bicarbonate (Lonza), 
and 5 mM sodium butyrate. 293FT supernatants were collected at 46-hours after 
transfection, neutralized with 1M Tris-HCl, pH 7.5 to 50 mM final concentration, and 
filtered through a 0.45 µm polyethersulfone syringe filter. Supernatants were then 
concentrated using Lenti-X concentrator (Clontech) and re-suspended in 
Neurobasal/B27. Lentiviral titer was determined using an ELISA-based quantification 
of p24 viral coat protein according to the manufacturer’s instructions (Clontech). 
Lentivirus was added to iPSC-derived neuron cultures 1-2 days after splitting of 
NPCs at the MOIs indicated. 
 
gRNA design and construction.  gRNAs were designed using the Zhang lab 
CRISPR design tool (crispr.mit.edu). gRNA sequences targeting PSEN1 (Table 2.3) 
were cloned into plasmid MLM3636 (a gift from Keith Joung, Addgene # 43860) as 
previously described (Fu et al., 2013). Briefly, DNA oligonucleotides were annealed 
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to generate double-stranded fragments that were ligated into BsmBI-digested 
plasmid.   
 
Design of ssODN repair templates.  100-nt ssODN repair templates (PAGE-
purified, IDT) were designed with homologous genomic flanking sequence centered 
around the predicted CRISPR cut site and containing pathogenic and/or CRISPR-
blocking mutations (Table 2.4). CRISPR-blocking silent mutations were selected 
based on codon-usage of the edited gene by changing the codon to another codon 
already used in the same mRNA for the respective amino acid. 
 
CRISPR/Cas9 gene editing. iPSCs were transfected with Cas9- and gRNA-
expressing plasmids, and ssODNs by electroporation. 2 million cells were 
resuspended in 100 µL cold BTXpress electroporation buffer (Harvard Apparatus) 
with 20 µg pCas9_GFP (a gift from Kiran Musunuru, Addgene plasmid # 44719), 5 
µg gRNA plasmid, and a total of 30 µg ssODN (oligo mixing of WT and mutant 
ssODNs was used to obtain heterozygous clones; a 1:1 ratio of WT:MUT ssODN 
was used in all experiments (Paquet et al., 2016)).  Cells were electroporated at 70 
mV for 20 ms in a 1 mm cuvette (Harvard Apparatus).  After electroporation cells 
were transferred to Geltrex-coated cell culture plates and grown in MEF-conditioned 
HUESM containing ROCK inhibitor for 2 days.  In all transfections, 7889SA-derived 




Recombinant tau preparation and aggregation. Recombinant tau was produced 
in Dr. David Eliezer’s lab by transfecting E. coli BL21/DE3 cells (Novagen, San 
Diego, CA) with plasmids encoding FL-WT tau (2N4R) or 4RD tau. These cells were 
lysed via sonication, and cellular debris was pelleted by ultracentrifugation at 
150,000 x g. Tau was further purified by cation-exchange chromatography, followed 
by reverse-phase high-performance liquid chromatography (HPLC). Purified tau 
protein was lyophilized and stored at -20°C.  
Following a protocol generated by Dr. Marc Diamond, lyophilized tau protein 
was weighed first resuspended in 10mM DTT to a final concentration of 800 µM and 
incubated at room temperature for 1 hour. This preparation was further incubated in 
10mM HEPES, 100 mM NaCl, with or without 8 µM heparin to generate aggregates 
or monomers respectively, with a final concentration of 8 µM tau. This preparation 
was allowed to incubate at 37°C for 24 hours. Aggregates, monomers and vehicle 
were subsequently snap-frozen in liquid nitrogen in single use aliquots, and stored at 
-80°C. 
 
HEK293 Biosensor Cell Culture. Human embryonic kidney (HEK) 293 cells that 
expressed a tau P301S RD fused to a CFP/YFP FRET pair was gifted from Marc 
Diamond (ATCC). Biosensor HEK293 cells were maintained in DMEM with 10% 
FBS, 2 mM Glutamax and 100 U/mL-0.1 mg/mL penicillin-streptomycin (all Life 
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Technologies) at 37 ºC with 5% CO2.  HEK293 cells were seeded on 96-well plates 
at 50,000 cells/mL. Cells were treated with DMSO control or inhibitors at the 
following concentrations: Pitstop 2 20 µM (Sigma), Cytochalasin-D 1 µM (Sigma), 
Latrunculin 1 µM (Sigma), Heparin 20 µg/mL (Sigma), Sodium Chlorate 25 mM 
(Sigma), 5-N-ethyl-N-isopropyl-amiloride (EIPA) 1 mM (Sigma), Lactacystin 10 µM 
(Sigma).   
 
Immunocytochemistry and microscopy.  Cells were fixed in 4% 
paraformaldehyde, permeabilized in PBS/0.1% TritonX-100 and stained with primary 
and secondary antibodies (see below). Stained cells were imaged on a Nikon 
Eclipse Ti inverted microscope and acquired using NIS Elements imaging software 
(Nikon). Fiji (www.Fiji.sc / National Institutes of Health) and Adobe Photoshop were 
used to pseudo-color images, adjust contrast, and add scale bars.  
 
Fluorescence activated cell sorting.  GFPhi and GFPlow cells were collected in the 
Rockefeller University Flow Cytometry Resource Center using a FACSAria II flow 
cytometer (BD Biosciences).  48h following transfection, cells were resuspended in 
PBS with 0.5% BSA fraction V solution, 10 mM HEPES, 100 U/mL-0.1 mg/mL 
penicillin-streptomycin (all from Life Technologies), 0.5 M EDTA, 20 mM glucose, 10 
ng/L DAPI in the presence of ROCK inhibitor for iPSC sorts. For single-cell derived 
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iPSC clone derivation, 30,000 – 70,000 GFP+ cells were immediately plated on a 
10-cm plate of MEFs in HUESM and ROCK inhibitor following cell sorting.  
 
Sanger sequencing for genotyping single cell clones.  To assess zygosity of 
genome edited single cell-derived iPSC clones, colonies on MEF-containing 10 cm 
plates (in HUESM + ROCK inhibitor) were manually picked into a single well of a 
Flat-bottom 96-well tissue culture plate in 100 µL HUESM + ROCK inhibitor.  Cells 
were pelleted by centrifugation, and plates were immediately frozen in liquid N2 and 
stored at -80 ºC. 
 Genomic DNA was extracted as previously described (González et al., 2014).  
Briefly, cells were resuspended in 25 µL lysis buffer (10 mM Tris-HCl (pH 7.6), 10 
mM EDTA, 20% SDS, 10 mM NaCl, 1 mg/mL Proteinase K (Ambion)), and 
incubated at 55 ºC for overnight.  Proteinase K was inactivated by incubating plates 
at 96 ºC for 10 min. The genomic region surrounding the PSEN1 loci was amplified 
by Taq polymerase (Roche) according to the manufacturer’s directions and genome-
edited clones were identified by RFLP analysis (Table 2.4). Clones with HR-
mediated incorporation of the CRISPR-blocking silent mutation (determined by 






Table 6.2. Primers for PCR amplification, RFLP analysis, and sanger 
sequencing for CRISPR/Cas9 genome editing of PSEN1. 
 
 
Cortical neuron differentiation.  iPSC-derived cortical neurons were generated as 
previously described (Shi et al., 2012b) with modifications.  Specifically, to generate 
neural precursor cells (NPCs), iPSCs were plated on 12-well tissue culture plates 
coated with Geltrex (Life Technologies) in MEF-conditioned HUESM with ROCK 
inhibitor.  When cells were 100% confluent, medium was replaced with neural 
induction (NI) medium (day in vitro 0 (DIV0)) and maintained for 8 days.   On DIV8 
day cells were dissociated using Accutase (Life Technologies) and resuspended in 
NI medium at 30 million cells/mL.  Cells were plated on dried poly-L-ornithine 
(Sigma-Aldrich) and laminin-coated (Life Technologies) 6-well plates in 200 µL 
spots.  Cells were left to adhere for ~45 min and NI medium was added.  On DIV10 
NI was replaced with neural maintenance (NM) medium.  Upon the appearance of 
neural rosettes, 20 ng/mL FGF2 was added for 2 days.  When neurons started to 
form (~DIV21), rosettes were isolated manually after treatment with STEMdiff Neural 
Rosette Selection Reagent (STEMCELL Technologies) for 1 h.  Rosettes were 
washed and plated on poly-L-ornithine/laminin-coated 6-well plates.  7 days after 
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rosettes were plated, the NPCs were expanded, again with STEMdiff Neuroal 
Rosette Selection Reagent (STEMCELL Technologies) for 1.5hr. NPCs were 
washed and plated on poly-L-ornithine/laminin coated 6-well plates. Between DIV35 
and DIV 38 NPCs were frozen in NM supplemented with 10% DMSO and 20 ng/mL 
FGF2. 
 For cortical neuron maturation, ~600,000-1,000,000 NPCs were plated on 12-
well poly-L-ornithine/laminin-coated plates and maintained in Neurobasal medium 
supplemented with B-27 serum-free supplement, 2 mM Glutamax and 100 U/mL-0.1 
mg/mL penicillin-streptomycin (all Life Technologies).  During the first 7 days after 
plating, cells were treated with 10 µM DAPT (Sigma-Aldrich) to augment neuronal 
maturation. 
 
Western Blotting. Neurons were harvested and RNA and protein were purified 
using the NucleoSpin RNA/Protein kit (Macherey Nagel) according to the 
manufacturer’s instructions. Lysates were run on Criterion™ TGX™ 4-20% precast 
gels for SDS-PAGE at 100V, or Criterion™Tris-Tricine 10-20% precast gels for SDS-
PAGE of APP b-CTFs at 100V (Bio-Rad). Gels were then blotted using standard 
techniques onto an Odyssey nitrocellulose membrane (LI-COR). Membranes were 
blocked in 5% non-fat dairy milk in TBS-T, and were probed with primary antibodies 
listed above. IRDye conjugated secondary antibodies (LI-COR) were used at 




Antibodies.  The following antibodies were used: Oct4 (1:500, Stemgent S090023), 
Tra160 (1:500, Millipore MAB4360), SSEA4 (1:500, Abcam ab16287), Nanog 
(1:500, Cell Signaling 4903), MAP2 (1:2000, Abcam 5392), Tuj1 (mouse 1:1000, 
Covance MMS-435P / rabbit 1:1000, Covance MRB-435P), Presenilin-1 NTF (1:500 
Milipore MAB1563), Presenilin 1 CTF (1:500, Milipore MAB5232), Nicastrin (1:5000, 
Milipore MAB5556), PEN2 (1:1000, Abcam ab18189), Aph1 (1:1000, Milipore 
ABC1696), APP C-term (1:10000, Abcam Y188 ab32136), Presenilin-2 (1:1000, Cell 
Signaling 9979), K9JA (1:10000 (WB), 1:500 IF, Dako), HT7 (1:1000, Thermo-
Fisher), MC1 (1:1000; gift from Peter Davies )(anti-mouse/rabbit/rat/chicken Alexa 
Fluor 488/568/647 (Invitrogen 1:500). 
 
Amyloid-β measurements.		Aβ was measured in cell supernatant conditioned for 1 
day (DIV8 NPCs), or 7 days (~DIV60 cortical neurons) after full media washout. 
Experiments were performed in 3 biological replicates. Supernatants from 
experiments collected at different time points were frozen at -80 ˚C.  Secreted Aβ1-
38, Aβ1-40 and Aβ1-42 was measured with MSD Human (6E10) Aβ V-PLEX kits 
(Meso Scale Discovery) according to the manufacturer’s directions.  Secreted 
sAPPα and sAPPβ were also measured simultaneously, and from matching 
supernatants, with MSD sAPPα/sAPPβ kit (Meso Scale Discovery) according to the 
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manufacturer’s directions. NPC and neuronal total Aβ levels were normalized to total 
sAPPβ levels (Meso Scale Discovery). 
 
Mice. Animals were bred according to IACUC protocols at the Rockefeller 
University. Newborn mice (P0) were collected from either ROSA26-EGFP (Giel-
Moloney et al., 2007), or CD1 WT mice (Jackson Laboratories). 
 
Statistical Analysis.  Experimental data was analyzed for significance using 
Graphpad Prism 7. P < 0.05 was considered statistically significant. All experiments 
were analyzed by one-way ANOVA followed by post testing with Dunnett’s method, 
as alterations were compared to controls.  
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